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Abstract 
 ii  
Abstract 
B cells are the antibody producing cells of the mammalian immune system and are 
formed through a differentiation and maturation process in the bone marrow. The 
glycophosphatidylinositol (GPI)-linked cell surface receptor CD24 causes apoptosis in 
the earliest B-cell developmental stages. As it has no transmembrane domain, the signal 
transduction mechanism of CD24 is not well understood and is the focus of this thesis. 
Using a bioinformatics approach, several genes were identified that are involved in 
apoptosis, cytoskeletal organization and endocytosis and whose pattern of expression 
tightly correlated with CD24. In addition, it was shown that extensive crosslinking of 
CD24 is required to mediate apoptosis in primary B-cells. Moreover, following 
crosslinking, CD24 protein is rapidly transported to the cell surface and then endocytosed. 
Lastly, it was observed that CD24 mediates homeotypic adhesion and is closely 
associated with cell-cell junctions. These data may provide new insight into the 
mechanism by which GPI-linked receptors activate intracellular signalling pathways. 
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CHAPTER 1: INTRODUCTION 
1.1 B Cell development 
B lymphocytes are an important cell type in adaptive immunity. Their primary 
function is to produce antibodies (Abs) against foreign macromolecules, termed antigens, 
as part of the immune response (1). Mammalian B lymphocytes (B cells) arise through a 
development process that requires stem cells to become committed to the B cell lineage 
following a highly regulated maturation process in the bone marrow (2, 3). The overall 
goal of B cell development in the bone marrow is to create a functional B cell receptor 
(BCR) that is capable of recognizing foreign antigens but cannot bind self-antigen. This 
process depends on sequential expression of the different components of the BCR as well 
as other accessory proteins necessary for overall B cell function. 
Hematopoietic stem cells (HSC) reside in the bone marrow and give rise to all 
blood cells, including B cells (3). HSC first become restricted to developing a single cell 
type, which is termed lineage commitment. HSC’s that become lymphoid committed are 
termed Common Lymphoid Progenitors (CLP), which become further committed to one 
of the lymphoid cell lines, such as B cells, T cells or Natural Killer cells (3). The defining 
characteristic of B cells is their expression of the B Cell Receptor (BCR), which is made 
up of multiple proteins of the immunoglobin (Ig) superfamily (Fig. 1.1). The antigen (Ag) 
binding portion of the BCR is a heterodimer consisting of two identical heavy chains 
(IgH) and two identical light chains (IgL), which form the membrane-bound Ab (mbAb) 
(1). This structure is anchored to the plasma membrane via a transmembrane domain (4). 
The mbAb forms a complex with CD79α and β (also known as Igα/β), which activates 
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Fig. 1.1: The B cell Receptor. The completed B cell receptor consists of two IgH heavy 
chains and two IgL light chains bound by disulfide bonds. Antigens are bound by the 
antigen recognition site defined by the V(D)J segments. Signal transduction occurs 
through the associated CD75A/B proteins (also known as the Ig α/β) through the 
immunoreceptor tyrosine-based activation motif (ITAM) structure. 
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signal transduction pathways in response to binding of the mbAb to antigen (Ag) (4).  
The development of B cells is divided into phases that are defined by the 
successful formation of various BCR components (1). Both the IgH and IgL chains of the 
BCR are encoded from rearrangement of different gene segments termed Variable (V), 
Diversity (D), and Joining (J), followed by a Constant (C) region (5). There are two light 
chain gene loci (termed kappa and lambda) that are composed of several V and J gene 
segments followed by a constant region. During formation of the light chain, only the 
kappa or the lambda loci will be expressed. The mature light chain consists of a single V 
and J gene segment combined with a constant region (5). The heavy chain loci contain V, 
D and J gene segments and one of 5 possible constant region isoforms, Alpha, Delta, 
Epsilon, Gamma and Mu. The BCR is mostly commonly expressed as the Mu, and Delta 
isoforms (IgM and IgD) but can also exist in the other isoforms depending on the cell 
type and developmental stage (5). These gene rearrangements occur at different times 
within the B cell maturation process. The earliest developing B cells, termed progenitor 
(pro-) B cells, begin rearranging the IgH gene, and this process is completed at the final 
stage of the pro-B cell development phase (6). During this phase the V, D and J gene 
segments of IgH recombine with a Mu constant region to form the IgH chain. Also during 
this time, a second structure termed the surrogate light chain (SL) is also formed to serve 
as a placeholder before the proper IgL chain is formed (6). The expression of the 
combined IgH/SL protein on the cell surface acts as the pre-B cell receptor and marks the 
transition of pro-B cells to precursor, or pre-B cells (3, 6). Pre-B cells are now required to 
complete the formation of the IgL chain and express the completed BCR (consisting of 
the IgH/IgL structure) on the cell surface. As such, an analogous process to IgH 
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rearrangement occurs in the light chain genes between the V and J segments and its 
constant gene (5). After successful generation of the IgH and IgL chains, a BCR is 
expressed on the cell surface. At this point, the cell is termed immature and is released 
from the bone marrow into peripheral lymphoid tissues such as the spleen or lymph nodes 
(2). The antigen recognition site (defined by the V, D and J segments) of the B cell 
receptor is identical to the antibodies a given B cell can express. 
 The B cell development process is highly stringent and large numbers of cells are 
purged via apoptosis at multiple checkpoints (7). Many potential B cell receptors can be 
generated from the genome, and this process is random. In effect, the number of 
potentially useful BCRs is dwarfed by the generation of inappropriate receptors. These 
receptors are subjected to a process termed allelic exclusion. Editing may occur during 
formation of either the IgH or IgL chains. Initially, IgH or IgL rearrangement occurs on 
only one of the sets of alleles (one on each parental chromosome). When non-functional 
IgH chains are formed, B cells are induced to attempt rearrangement from the unused 
chromosome. Failure a second time to generate a functional BCR results in apoptosis of 
the pro-B cell. Similarly, the IgL chain can undergo allelic exclusion where failure also 
results in apoptosis.  
 Of greater concern to generating non-functional receptors is the formation of 
BCRs that recognize self-antigen. To become active and produce antibodies, B cells must 
receive signals through the BCR and other co-stimulatory receptors such as CD40 (8). 
Recognition of self-antigen would normally occur in the absence of co-stimulation and 
these B cells would also be purged through apoptosis (8). This process is imperfect, 
Introduction 
 5 
however and occasionally B cells may survive this selection process, which can lead to 
the development of autoimmune disease. 
B cell development is a delicate balance between receiving appropriate growth 
and differentiation stimuli, and the induction of apoptosis (6). Indeed, it is at the pro- to 
pre- B cell checkpoint that CD24 is thought to function, potentially, as a gatekeeper to 
downstream development (9, 10). Assuming a cell passes these checkpoints immature B 
cells travel to secondary lymphoid structures and undergo further maturation before 
entering a quiescent phase as a naïve B cell. It is these naïve B cells that can bind antigens 
and receive appropriate co-stimulation from T lymphocytes to produce antibodies (1). 
 
1.2 The Hardy fractions 
The pro-B and pre-B cell developmental stages have been further refined into 
more discrete phases with the advent of Fluorescent Activated Cell Sorting (FACS).  
FACS works on the principle of tagging cell surface proteins typically using antibodies 
labelled with fluorescent molecules. These antibodies can then be detected by a flow 
cytometer using lasers at a set wavelength, which excites the fluorophore with the 
subsequent emission registered by a photomultiplier tube or charged couple device (11). 
As such, it became possible to delineate cell populations based on the expression of 
characteristic surface markers, and also to quantify the relative expression of these 
markers among different samples.  
In seminal work, Richard Hardy and colleagues (2, 12) used FACS to subdivide 
the pro- and pre-B cell fractions into more discrete stages (Fig. 1.2). The earliest marker  
Introduction 
 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2: The Hardy Fractions and B Cell Developmental Markers. Fr stands for Hardy Fraction. CD19 and B220 are used as 
pan-B cell markers in the bone marrow. CD43 expression defines the pro-B cell phase, which is further subdivided by CD24 and 
BP-1 expression. The development of B cell receptor proteins defines the pre- and immature B cell phases. Adapted from Hardy, 
et al 1991 (2, 12). 
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expressed on cells that will become B cells is transmembrane protein B220, also known 
as protein tyrosine phosphatase receptor type C (PTPRC) or CD45R. Thus, Hardy et al. 
(2) began by dividing cells into those that express B220 (B220+) from those which did 
not (B220-). All cells expressing B220 were considered developing B cells, while the rest 
were excluded. These B220+ cells were similarly subdivided into CD43+ and CD43- 
populations, corresponding to pro- and pre-B cells, respectively. The CD43+ pro-B cells 
could be further divided into 3 groups, termed fractions A, B and C using expression of 
CD24 and BP-1 (Glutamyl Aminopeptidase). Fraction A was CD43+, CD24- and BP-1-; 
Fraction B; CD43+, CD24+ and BP-1; and fraction C; CD43+, CD24+ and BP-1+ (2). 
Subsequent experiments proved that these fractions demonstrated a temporal relationship 
with fraction A being the most immature and giving rise to B and then on to C (2). Hardy 
et al. (2) also determined that the C fraction contained a subpopulation which had higher 
expression of CD24 and was subsequently termed Cʹ. Similarly the CD43-, pre-B cells 
were divided into fractions D, E and F using their relative expression of the IgM isoform 
of the BCR and B220.  
Further research by Hardy and others determined that while B220 is expressed on 
all bone marrow B cells, it is also expressed in a variety of other isoforms in multiple cell 
types (13) and cannot unambiguously denote any given cell populations in the absence of 
other markers (14). Subsequently, CD19 has proven to be a better marker for B cells in 
the bone marrow as it is expressed on all cells in fractions B through F (3, 15). Although 
CD19 is not expressed on Fraction A cells, more recent research has found that cells in 
fraction A are heterogeneous and are not yet fully committed to the B cell lineage (3, 16) 
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Thus, CD19 expression in the bone marrow now serves as a gold standard marker for in 
vivo, ex vivo, and in vitro work on bone marrow-derived B cells.  
 
1.3 The CD24 cell surface receptor 
 As identified by Hardy and others, CD24 (also known as Heat Stable Antigen or 
Nectadrin) is differentially expressed during B cell development in mice (2, 17). Human 
CD24 is also differentially expressed between developing and mature B cells (17). It was 
reported that the highest CD24 expression corresponded to immature developing B cells 
and upon maturation expression was reduced (17). Later research demonstrated that 
CD24 expression was not permanently abolished. In peripheral lymphoid tissues mature 
B cells undergo a brief terminal differentiation before they have the ability to be 
activated. These cells are termed Transitional B cells and CD24 expression is regained 
(18) during the earliest part of this process (18). Once mature, B cells lose most or all of 
their CD24 expression (18, 19). 
CD24 was first isolated in 1978 as part of a project to generate rat antibodies 
against mouse B cell surface proteins (20, 21). The protein was isolated using the 
antibodies M1/69 and M1/75 and named Heat Stable Antigen (HSA) in accordance with 
its high thermal stability. The human gene was isolated in 1991 and both the mouse and 
human CD24 genes were shown to be approximately 240 bp with a long, ~1.6 kb 3’ 
untranslated region (UTR) (Fig. 1.3). The final mature protein is very short, containing 27 
or 31 amino acids in the mouse or human version, respectively. The mature protein is also 
extensively and variably N- and O- glycosylated (22) in a tissue-specific fashion. Thus 
the final weight of the protein can range from 20 to 80 kDa (23).  
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Fig. 1.3: CD24 in Human and Mouse. A. Human CD24 (6q21). Total mRNA transcript 2194 bp B. Mouse CD24A (10 23.01 
cM). Total mRNA transcript 1825 bp. Information retrieved from NCIB Entrez ID 12484 (Mouse) and 100133941 (Human). 
Green lines represent genomic structure with dark green indicating coding regions and light green the 5’ and 3’ untranslated 
regions. Exons are denoted by thick lines, introns by thin lines. Blue represents the primary mRNA transcript and red represents 
the processed mRNA for protein translation. C. Schematic representation of CD24 on the cell surface. The core protein is linked 
by a GPI anchor. O-linked glycosylations are likely on C and N-terminal regions, with N-linked glycosylations towards the 
center.  
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The CD24 protein is bound to the outer leaflet of the cell membrane through a 
glycosylphosphatidylinositol (GPI) anchor in both mouse and human cells (24). This 
glycolipid structure could be cleaved using Phospholipase C, which subsequently 
removed the protein from the membrane (24). This established conclusively that mature 
CD24 has no transmembrane structure, but left unaddressed questions as to how it might 
function.  
A variety of different CD24 ‘forms’ have been identified due to the differential 
pattern of glycosylation found on the protein when isolated from various tissues. 
Therefore it is not unexpected that several potential ligands for the receptor have also 
been identified. Research into CD24 activity in the small lung cell cancer line SW2 and 
the breast cancer cell line KS demonstrated a high affinity binding for P-selectin (25, 26), 
but not the other selectins, suggesting a highly specific affinity (26). CD24 protein 
isolated by affinity purification interacts with CD171, a cell adhesion molecule also 
known as L1 and is known to promote neurite outgrowth (20). Finally, in hematopoietic 
cells, CD24 is known to bind P-selectin and so-called Danger Associated Molecular 
Patterns (DAMPs) and Siglec G in a trimeric protein moiety (20, 27). CD24 has even 
been shown to engage in homotypic interactions. This wide range of binding partners and 
highly variable nature of the post-translational modifications supports the argument that 
CD24 may participate in an unusually diverse repertoire of physiological functions. Based 
on this diversity, CD24 may arguably be considered to be a pseudo-family of proteins that 
share a common protein motif and variable carbohydrate branch ‘isoforms’. Despite its 
first discovery in the late 1970’s (21), and its subsequent isolation from a wide range of 
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cell types, little is known about the underlying role of CD24 in B cell development, and 
less is known about the mechanism through which it operates.  
 
1.4 CD24 regulates cell survival and adhesion in a cell type dependent manner 
CD24 is expressed in a wide variety of cell types and is known to mediate 
differing processes such as cell adhesion, cell-fate decisions, or participate in cell cycle 
control and pro-life/pro-death responses depending on the source of the cell type 
examined. One of its earliest established functions was in cell-cell adhesion between B 
cells. (28). CD24 is now also known to regulate cell adhesion in developing neuronal 
tissue (20) while also participating in synaptic transduction (29) and neuronal growth. 
Other studies have shown that CD24 moderates tumour cell invasiveness and is 
associated with increased cell proliferation (23). In other studies relating to its role in 
tumour biology, CD24 has proved to be a valuable biomarker in several malignancies, 
including carcinomas, sarcomas, lymphoma and leukemia. Shortly after the genomic 
sequence of CD24 was identified, it was found that CD24 is highly expressed on small 
lung cell carcinoma (30). CD24 was also highly overexpressed in a majority of 
hepatocellular carcinoma samples from 79 human samples, but not expressed in non-
tumour liver cells (31). In 2002, increased CD24 expression was identified to be a highly 
significant prognostic indicator of decreased survival time in ovarian cancer (32), non-
small cell lung cancer (33) and glioma (34). Moreover, inhibition of CD24 expression in 
hepatocellular carcinoma and breast cancer cell lines showed a decrease in cellular 
proliferation (35, 36). Together, these data show CD24 is active in a wide range of 
cellular contexts. 
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Research from these diverse fields has consistently demonstrated that CD24 
functions as a cell surface receptor, mediates the way cells adhere to neighbouring cells, 
and moderates the balance between pro-apoptotic and pro-survival signals, As such, it 
provides context to examine the role of CD24 in B cells as these same functions are 
dynamically regulated in the bone marrow during B cell development. First, B cell 
development is critically dependent on receiving and responding to time-appropriate 
signalling events from external factors, such as Interleukin-7 (IL-7) secreted by stromal 
cells (37). Second, early progenitor B cells are contact-dependent on the bone marrow 
stroma but release from the stroma upon transition to the pre-B cell development stage (2, 
38). Third, these cells must also tightly regulate the pro-proliferative and pro-apoptotic 
signals they receive to ensure only appropriate B cells exit the bone marrow (39, 40). We 
can therefore argue that while the cellular context may be different, the underlying role of 
CD24 appears to be involved in mediating these pro-survival vs. pro-apoptotic events and 
thus insight into CD24 is broadly applicable to many disciplines. 
 It was established early that CD24 was a signalling molecule in B cells (17, 41) 
but much of the earliest research focused instead on its role in cell adhesion (42). One of 
the earliest studies on CD24-mediated adhesion examined its role in multiple cell types 
(28). CD24 was found to be preferentially expressed at the junctions between cells in B 
lymphocytes, neuroblastoma and neuronal cells. Furthermore, CD24 was isolated from B 
cell lymphoma cell line ESb 289 in two major isoforms: a large, 40-60 kDa and small 23-
30 kDa form. The larger form was shown to have strong homotypic (self) binding 
properties, and it was shown that blocking CD24 with mouse monoclonal antibody 79 
(mAb79) antibodies abolished this (28). The smaller form was suggested to be a cleavage 
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product from the larger, through removal of specific glycosylations, and did not mediate 
this binding. This suggested that CD24 can have different roles depending on the form 
expressed by the cell, although this was not clearly established. Kadmon et al.(28) 
demonstrated that CD24 functioned in neurons through interactions with L1 and Neuronal 
Cell Adhesion Molecule (N-CAM) on the same cell (43). The results clearly 
demonstrated that CD24 actively moderated the signalling response as engagement of 
both CD24 and L1 together resulted in a 6- to 10- fold increase in intracellular calcium 
than when they were engaged individually (43).  
 Despite the evidence for its role in signal transduction, it was over 20 years before 
an endogenous ligand, other than itself, was identified for CD24. It was hypothesized that 
the extensive and variable carbohydrate motifs (glycosylations) may be part of the 
mechanism by which CD24 could mediate different downstream events through multiple 
ligands (26). Multiple studies have shown that P-selectin, one member of the lectin family 
of carbohydrate binding proteins normally expressed on endothelial cells and platelets, 
bound to CD24 (25, 26). This binding was established to be highly specific, as a closely 
related protein, E-selectin, did not bind (26). Changing the glycosylations by treatment 
with O-sialoglycoprotein.endopeptidase, which removes O-linked glycosylations from 
CD24, abrogated this binding (25). These results established that P-selectin was 
specifically binding to CD24 in humans. Further research has also shown that the CD24-
L1 interactions in neuronal cells are dependent on the presence of sialic acid bound to the 
CD24 protein (44). Removal of the sialic acid abrogated CD24 binding in this cellular 
context (44). The intracellular signalling events mediated by CD24-ligand binding were 
not identified at this time, but have been the focus of subsequent work. 
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Despite evidence that CD24 affects intracellular processes and the discovery of an 
endogenous ligand, little had been demonstrated with regard to the mechanism of how it 
signals. While Kadmon et al. (28) showed that CD24 interacted to co-operatively signal 
with cell adhesion molecules, nothing was known about CD24’s intrinsic signalling 
properties. Evidence that CD24-mediated Src Protein Tyrosine Kinase (PTK) activation 
in T cells (45) was one of the first results demonstrating that CD24 directly interacts with 
signalling proteins. Further research in B cells showed that CD24 induces the rapid 
phosphorylation of the mitogen-activated protein kinases (MAPK) ERK, p38 and Jun 
amino-terminal kinases (JNK)/Stress-Activated Protein Kinases (SAPK) (46). These 
findings were the first data to identify a downstream signalling pathway that participates 
in CD24-mediated regulated of apoptosis. In subsequent studies in colorectal cancer cells, 
CD24 was shown to regulate ERK activation as a mechanism for controlling cellular 
proliferation (34, 47). Taken together, these results firmly established that CD24 has an 
active role in mediating cell proliferative events in multiple cell types, including B cells 
and cancer cells.  
 
1.5 The role of CD24 in B cell development 
CD24 expression in murine B cells has been known since 1978 (21). The first 
study to demonstrate a role for CD24 in B cell development was not published until 1990 
(27). The previously discussed dynamic regulation of CD24 expression, which is highest 
at the pro- to pre-B cell transition, is strongly suggestive of a functional role at this 
developmental checkpoint. Research at this time established that CD24 functioned as a 
cell adhesion molecule (28). Furthermore, Hahne et al. (42) demonstrated that CD24 
Introduction 
 15 
actively moderated the ability of pre-B cells to attach to bone marrow stroma by altering 
adhesion of the integrin Very Late Antigen-4 (VLA-4) to Vascular Cell Adhesion 
Molecule 1 (VCAM-1) and fibronectin (42). In the presence of CD24, VLA-4 binding to 
VCAM-1 can be inhibited using anti-VCAM-1 antibodies. In the absence of CD24, VLA-
4/VCAM-1 binding cannot be blocked, and VLA-4 is also unable to bind to fibronectin 
(42). Adhesion of B cells to bone marrow stromal cells is a critical requirement for early 
(progenitor) B cell development (2, 48, 49). Indeed, it has been demonstrated that 
Fraction A was stromal-contact dependent for survival and that by Fraction C, B cells 
must release from stroma, but are still dependent on secreted cytokines, most notably IL-7 
(2, 50, 51). During bone marrow development, IL-7 is produced by stromal cells and is 
critical for the early survival of pro-B cells (2, 50, 52). In both pro-/pre- B cell and 
Transitional B cell developmental time points in which CD24 is highly expressed, B cells 
must either regulate their interaction with neighbouring cells to receive particular growth 
or differentiation signals, or they are induced to undergo apoptosis (53, 54). It is thus 
reasonable to hypothesize that CD24 is actively engaged in this process and that it may 
potentially serve as a check for receiving developmentally appropriate signals from 
physical interactions. 
 While these results provided correlative data for potential CD24 interactions in 
developing B cells, no specific results had yet established precisely how, or even if, CD24 
was functionally important in bone marrow B cell maturation. To establish an 
unambiguous role for CD24, Wenger et al.(55) developed a novel CD24 knockout mouse 
strain in embryonic stem cells as a model to study hematopoiesis in the absence of CD24 
(55). Mouse strains were made to be either single knockout (CD24-/+) or double knockout 
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(CD24-/-) where the CD24 gene was removed in one or both homologous chromosomes, 
respectively. To determine the effect of CD24 knockout on B cell development, 
lymphocytes from CD24-/- mice were compared to CD24-/+ or wild-type mice (55). The 
number of B220+, BCR+ B cells in the spleen was unaffected (55).  Interestingly, in 
CD24-/- mice the loss of CD24 resulted in a substantial reduction in the number of 
immature B cells. Specifically, the majority of lost cells corresponded to the 
B220+/CD43+/BP-1+, Fraction C and Cʹ cells, but not the earlier or later Hardy fractions 
(55). These lost cells normally have the highest expression of CD24 in the bone marrow 
and represent the transition from progenitor to precursor B cells. It is thus reasonable to 
conclude that CD24 is a key component of the control process by which this transition 
occurs. Interestingly, this also shows that the loss of CD24 is not a fatal developmental 
block as normal numbers of B cells are found in subsequent developmental stages (55, 
56), suggesting that there is increased proliferation of the cells that progress past the Cʹ 
stage to reconstitute the mature B cell population. Follow-up studies in these knockout 
mice demonstrated that despite the delay in development, the mature B cells were 
unimpaired in their ability to function (56). These data present two possibilities regarding 
CD24 activity. Either CD24 is not involved in generating B cells, but perhaps plays a role 
in their developmental timing or potentially as a quality control checkpoint, or there is 
some redundancy in the role CD24 plays in B cell development where the loss of CD24 
can be compensated.  
 The work of Wenger et al.(55) and Nielsen et al.(56) demonstrated that CD24 has 
a functional role in B cell development but did not establish how its effects were 
mediated. While the use of knockout mice successfully established that CD24 was 
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involved in B cell development, the use of transgenic mice that constitutively overexpress 
CD24 first demonstrated that CD24 induces apoptosis in immature B cells (9, 57). The 
CD24 gene, the T cell receptor (TCR) Vβ promoter and an immunoglobulin gene 
enhancer were cloned as a unit with multiple copies into an outbred mouse strain to 
generate mice that constitutively overexpress CD24. As T and B cells share a common 
lymphoid progenitor, the choice of the TCR Vβ promoter and Ig enhancer ensures that 
CD24 expression is high in all cells of lymphocyte origin. This construct resulted in a 
twofold overexpression of CD24 in the thymus, bone marrow, lymph nodes and spleen, 
representing all the sites of B cell maturation (9).  
Immature B cells from these transgenic mice were then used in ex vivo and in 
vitro assays to identify how CD24 overexpression affects B cell development. One of the 
first in vitro assays established that CD24 overexpression leads to a profound reduction in 
the formation of IL-7-responsive B cells (9). Bone marrow cells were isolated from 
CD24-transgenic mice and cultured in recombinant IL-7 (9) to establish B cell colonies. 
The responsiveness of CD24-transgenic mice to this assay was decreased (9) 
demonstrating a loss of IL-7-dependent lymphoid progenitors. This result was highly 
congruent with the previous data that demonstrated the developmental block at the pro- to 
pre- B cell transition, as pre-B cells lose their stroma and IL-7 dependency (2), suggesting 
that CD24 affects maturation of IL-7-dependent cells.  
Further categorizing the changes to B cell populations revealed that transgenic 
mice had significantly lower cell numbers in each Hardy fraction, the numbers of mature, 
splenic B cells was reduced, and their ability to respond to antigen in the form of 
membrane proteins from Escherichia coli was attenuated (9).  
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The loss of B cells in response to CD24 overexpression suggests that an increased 
level of CD24 artificially causes otherwise viable B cells to be lost. Taken together, the 
use of knockout and transgenic mice suggests that CD24 is not an absolute requirement 
for the generation of normal B cells, but is responsible for regulating apoptosis, 
potentially as a method of “quality control” in B cell development. The data from both the 
knockout and transgenic mouse studies suggest that CD24 may function to moderate early 
B cell development through its interactions with the bone marrow environment. In 
knockout mice, the loss of B cells may be due to their inability to form or regulate 
appropriate stromal attachment, depriving them of critical growth signals. In transgenic 
mice, overexpression of CD24 may delay or restrict the ability of these cells to release 
from the stroma and continue through the maturation process resulting in their 
elimination. 
The most recent work on CD24 activity in B cells has centered on first 
establishing if CD24 mediates apoptosis, and how this is accomplished. Several studies 
have examined this question using the transgenic mouse model and in vitro assays using 
immature B cell lines. Between 1996 and 2006, four major publications demonstrated that 
CD24 directly induces apoptosis in cells isolated from CD24-transgenic mice and several 
(but not all) murine and human immature B cells when stimulated with anti-CD24 Abs 
(19, 46, 57, 58). This technique, known as antibody crosslinking, mimics the interaction 
of CD24 with an endogenous ligand. Antibody crosslinking is an effective and essential 
method to stimulate CD24 as the native ligand for CD24 in the bone marrow has yet to be 
identified. Cells are incubated with a primary Ab that recognizes the receptor and a 
secondary Ab that recognizes the first Ab, potentially clustering up to 4 receptors given 
Introduction 
 19 
that each Ab has 2 identical Ag binding sites. Biologically this mimics established B cell 
signalling methods. For example, stimulating a single BCR is not sufficient to activate B 
cells, but the simultaneous activation of many receptors by clustering them together in 
one microdomain results in effective signal transduction (59).  
 The first publication to directly assess CD24-mediated apoptosis, by Chappel et 
al. (19), used either bone marrow-isolated B cells that were co-cultured in vitro with 
stromal cells or cytokines, or mature, splenic-derived B cells. Cells were stimulated using 
varying doses of the M1/69 anti-mouse CD24 Ab (primary), with or without secondary 
Ab against M1/69 (19). Engaging CD24 using both primary and secondary Abs resulted 
in increased apoptosis in the bone marrow-derived B cell cultures (19). This result was 
the first demonstration of a causal link between CD24 and apoptosis. This effect was 
restricted to the bone marrow, however, as the mature splenic B cells did not undergo 
apoptosis. Instead, these cells exhibited a dramatic decrease in proliferation in response to 
the receptor CD40 that normally will induce proliferation (19).  
Building on these results, an in vivo assay of immature B cell apoptosis in the 
CD24-overexpressing transgenic mice was performed (57). The rate of apoptosis in 
B220+ cell populations was measured in both transgenic and normal mice. Fresh, 
uncultured cell isolates from transgenic mice had an apoptotic rate nearly three times that 
of the normal cells (57). While these transgenic mice showed an exaggerated phenotype 
compared to normal animals, these results provide substantial support to argue that CD24 
directly induces apoptosis in developing B cells resident in bone marrow.  
 The major unanswered question regarding CD24 activity is the mechanism by 
which it can induce apoptosis. To that end, the most recent investigations have begun 
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examining the downstream effects of CD24 antibody crosslinking in human lymphoma 
cell lines developmentally arrested at the pro- or pre-B cell phase. The first information 
regarding a signalling method implicated a lipid-raft mediated system (46). Lipid rafts are 
thought to be signalling platforms in the plasma membrane. They are highly enriched in 
sphingolipids and cholesterol compared with the rest of the plasma membrane (60). The 
association of these sphingolipids and cholesterol result in a more stable structure in the 
membrane, which preferentially associates with proteins such as GPI-linked receptors, 
including CD24 (60). The components of a lipid raft are not permanent and thus the 
intracellular signal can be altered by including or excluding particular components (60). 
CD24 is known to be associated with lipid rafts (46) so attention was focused on other 
known lipid-raft signalling molecules including the Src-family PTKs. (45, 46, 61). This 
hypothesis was further reinforced by the previously discussed results that showed CD24 
interacts with Src-family proteins in T cells (45). 
CD24 crosslinking was demonstrated to selectively engage the Lyn PTK in lipid 
rafts and CD24 and Lyn co-localized to the lipid raft domains in the membrane (46). This 
study also produced the first clear data of a downstream signalling event in response to 
CD24 cross-linking in B cells. Crosslinking of CD24 was then shown to lead to the 
phosphorylation and activation of several mitogen activated protein kinases (MAPK). 
Within 3 minutes of cross-linking, high levels of activated Erk and p38 were detected. In 
the same experiment increased phosphorylated SAPK was found within 18 minutes (46). 
These results were further validated by subsequent research confirming CD24-mediated 
phosphorylation of p38, ERK and SAPK in other human lymphoma lines using primary 
and secondary antibody crosslinking (58). These MAPK proteins are known regulators of 
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cell survival and apoptosis and thus provide a potential target for future research. It was 
further demonstrated that this crosslinking causes activation of caspase proteins, which 
are known downstream mediators of apoptosis (58). Furthermore, Suzuki et al. 
demonstrated that the BCR may be involved in CD24-mediated signalling through 
translocation of the pre-BCR into lipid raft domains in response to CD24 cross-linking 
(46).  
Subsequently, it was shown that co-stimulating pre-BCR and CD24 abrogated the 
induction of apoptosis that normally occurs in response to stimulation of CD24 (58). How 
these receptors interact is currently unknown, but the pre-BCR is known to provide tonic, 
resting stimulation to pre-B cells to promote survival and proliferation (6, 58) and likely 
represents an intrinsic regulatory element in the control of apoptosis in negative selection. 
While these results are the first conclusive evidence for the downstream signalling of 
CD24, these cell lines are malignant, and may have altered regulation of pro-proliferative 
or pro-apoptotic pathways. 
 
1.6 Research Objectives 
Research objectives: 
1. To determine if WEHI-231 cells are an appropriate model system to 
investigate the regulation of CD24 expression in B cells. 
2. To determine the mechanism through which CD24 mediates apoptosis in 
bone marrow-derived immature B cells. 
To address these two questions I have used a combination of in vitro, 
bioinformatics, and ex vivo techniques. WEHI-231 cells, a murine immature B cell 
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lymphoma line, were used to address how CD24 expression is regulated during the 
transition from immature to mature, antibody-secreting cells. While cell lines cannot 
perfectly recreate in vivo biological processes, they are advantageous in that they remove 
much biological variability and simplify the inherent complexity of biological systems.  
To address how CD24 signals, bioinformatics data were used as a hypothesis 
generation tool followed by ex vivo techniques to validate the hypothesized biological 
functions in primary cells. This ex vivo work generated a highly controlled, homogenous 
system while preserving the intrinsic organization and regulation of cell signalling 
pathways.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Antibodies and Fluorophores 
 Rat anti-mouse CD40 (Clone 1C10) was purchased from Abcam (Cambridge, 
MA). The following antibodies were purchased from Jackson ImmunoResearch (Bar 
Harbor, ME): µ-chain specific goat anti-mouse IgM (Cat: 115-005-020); goat-anti-rat 
biotinylated IgG H+L (Cat: 112-065-003); goat-anti-rat IgG (IgH+IgL) (Cat: 112-005-
003). The following antibodies were purchased from eBioscience (San Diego, CA): Anti-
mouse CD24 functional grade purified (M1/69) rat IgG2b κ; rat IgG2b κ isotype 
functional grade purified; anti-mouse CD24-FITC (M1/69) rat IgG2b κ; anti-mouse 
CD19-fluorescin isothiocyanate (FITC) (1D3) rat IgG2a κ; rat IgG2a κ-FITC; anti-mouse 
CD43-Phycoerythrin (PE) (eBioR2/60) rat IgM; rat IgM κ-PE; rat anti-mouse CD19-PE-
Cy5.5 (eBio 1D3) rat IgG2a, κ; rat IgG2a κ (eBR2a)-PE-Cy5.5 Isotype; anti-mouse 
CD19-Peridinin chlorophyll (PerCP)-Cy5.5 (eBio1D3) Rat IgG2a κ; rat IgG2a κ-PerCP-
Cy5.5; anti-human/mouse CD45R (B220)-eFluor660 (RA3-6B2) rat IgG2a κ; rat IgG2a 
(eBR2a)-eFluor660. Normal rat IgG2a was purchased from Santa Cruz Biotechnologies 
(Santa Cruz, CA). Streptavidin-FITC was purchased from eBioscience (Cat: 11-4317-87) 
and Streptavidin-Rhodamine Red X (Cat: S-6366) from Invitrogen (Carlsbad, CA). 
 
2.2 Animal Care 
Three-week-old C57BL/6 male mice were obtained from the Quebec facility of 
Charles River Laboratories (Wilmington, MA) and housed in the animal care facility of 
Memorial University of Newfoundland. The Institutional Animal Care committee at 
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Memorial University of Newfoundland approved all animal procedures. Two to three 
animals were housed per cage in open-topped cages. Animals were sacrificed between 3 
and 8 weeks of age by cervical dislocation after isoflurane anaesthesia. 
 
2.3 WEHI-231 culture and treatment 
All media and supplements were obtained from Life Technologies (Burlington, 
ON) unless otherwise indicated. WEHI-231 (ATCC, Manassas, VA), a pre-B cell 
lymphoma cell line derived from BALB/c x NZB mice, were maintained in Roswell Park 
Memorial Institute (RPMI) 1640 Media supplemented with 10 % heat-inactivated foetal 
bovine serum (FBS), 1% antibiotic/antimycotic, 1 % sodium pyruvate and 0.1 % 
mercaptoethanol (hereafter referred to as RPMI complete media) at 37 C and 5 % CO2. 
Cells were maintained between 2x105 cells/ml to 1x106 cells/ml in 10 ml or 250 mL 
tissue culture-treated culture flasks. All experiments were performed in complete medium 
unless otherwise noted. 
  
2.3.1 Viability Assay (MTT) 
  WEHI-231 cells were plated in 80 L of RPMI complete media at 3.12x105 
cells/mL or 6.25x105 cells/ml in duplicate in a 96-well, flat bottom tissue culture-treated 
plate. The cells were treated with anti-IgM and anti-CD40 antibodies to a final 
concentration of 0 to 800 ng/mL and 0 to 1600 ng/mL, respectively (Table 2.1). After 24 
h, medium was removed and 90 µL of fresh medium with 10 µL of 5 mg/mL 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) from Sigma Aldrich  
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Table 2.1: Anti-IgM and Anti-CD40 antibody concentrations used to determine the 
optimal conditions to induce or block apoptosis in WEHI-231 Immature B-cells.  
 
anti-IgM / anti-CD40 (ng/ml)a 
0/0 50/0 100/0 200/0 400/0 800/0 
0/25 50/25 100/25 200/25 400/25 800/25 
0/50 50/50 100/50 200/50 400/50 800/50 
0/100 50/100 100/100 200/100 400/100 800/100 
0/200 50/200 100/200 200/200 400/200 800/200 
0/400 50/400 100/400 200/400 400/400 800/400 
0/800 50/800 100/800 200/800 400/800 800/800 
0/1600 50/1600 100/1600 200/1600 400/1600 800/1600 
 
a Numerator is the concentration of anti-IgM, denominator is the concentration of anti-
CD40. 
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(St. Louis, MO) dissolved in phosphate buffered saline (PBS, 100 mM Sodium 
Phosphate, 1.5 M NaCl) was added. Cells were incubated for 4 h and then 100 µL of 0.04 
N HCl in isopropanol was added to solubilize the precipitated formazan product. 
Absorbance was measured at 570 nm using a Powerwave XS UV/Vis Plate Reader from 
Biotek (Winooski, VT). 
 
2.3.2 CD24 Expression Analysis 
Five million cells at 6.25x105 cells/mL were cultured in RPMI complete media 
and treated with 400 ng/mL of anti-IgM for 6 or 24 h. To rescue cells from apoptosis, 
cells were co-stimulated with anti-CD40 at 800 ng/mL along with anti-IgM at the 
previously stated concentration. Additionally, 5.0x106 cells (6.25x105 cell/mL) were 
treated with Escherichia coli lipopolysaccharide (LPS) from Sigma Aldrich (St. Louis, 
MO) to a final concentration of 3 µg/mL, following the protocol described by Boyd et al. 
(62) or with LPS/anti-IgM/anti-CD40 for 6 or 24 hours. 
Cells were pelleted at 400 x g for 5 min and resuspended in 1 mL TRIzol 
(Invitrogen). RNA was extracted following the manufacturer’s protocol. Extracted RNA 
was eluted in 10 L RNAse/DNAse free water and concentration was determined using 
the Nanodrop 2000 spectrophotometer (ThermoScientific, Wilmington, DE). RNA was 
checked for integrity by gel electrophoresis in a 1% agarose gel and visualized with 
ethidium bromide (EtBR). RNA was stored at -80˚C. cDNA was synthesised from 500 ng 
of RNA from a working stock at 300 g/mL using the M-MLV RT kit (Invitrogen) 
following the manufacturer’s protocol. Polymerase Chain Reaction (PCR) amplification 
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from cDNA was performed using using the following primers from IDT (Coralville, IA): 
CD24: Forward 5’-CTTCTGGCACTGCTCCTACC-3’, Reverse 5’-
TTTCACGCGTCCTTTAATCC-3’; Ribosomal 18S Subunit: Forward 5’-
GACCATAAACGATGCCGACT-3’, Reverse 5’-GGCCTCACTAAACCATCCAA-3’; 
Large Ribosomal Protein (RPLPO): Forward 5’-CGGCCCGTCTCTCGCCAGG-3’, 
Reverse 5’-CAGTGACCTCACACGGGGCG-3’. The number of cycles that showed 
linear amplification was determined empirically as 32 cycles for CD24 and Ribosomal 
18s subunit and 24 cycles for RPLPO. PCR products were run on a 1% agarose gel and 
visualized with Ethidium bromide (EtBR). 
 
2.4 Bioinformatics analysis 
2.4.1 Microarray data 
MIAME-compliant microarray data sets were generated by the Immunological 
Genome Project (ImmGen) (63) from 5-week old C57BL/6 mice using the Affymetrix 
(Santa Clara, CA) Mouse Genome 1.0ST array (MoGene 1.0ST) platform to profile the 
expression of 35,556 features. Features included over 28,000 coding transcripts and over 
7,000 non-coding and control transcripts. Data files were accessed from the Gene 
Expression Omnibus (GEO), accession number GSE15907. To determine which genes 
are differentially expressed during B cell development, arrays for the Multi-lineage 
progenitor stem cell, Hardy fractions A, B/C, Cʹ, D, E, F, Transitional stage (T)1 and 
peritoneal-derived plasma cells (PC) were analyzed (Table 2.2). Analysis was performed 
in R, version 2.15.0 (64) using Bioconductor (65) packages as outlined below. The R-
scripts were generated in Tinn-R version 2.3.7.1 (66) before importing into the R  
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Table 2.2: Mouse Gene 1.0ST array sets from the Immunological Genome Project used to 
identify differentially expressed genes. 
 
Maturation Stage Abbreviation GEO Accession 
Numbers 
GEO File Name 
Multilineage 
Progenitor 
MLP GSM791124 
GSM791125 
GSM791129 
GSM791130 
MLP.BM#1 
MLP.BM#2 
MLP.BM#3 
MLP.BM#4 
Fraction A FrA GSM538351 
GSM538352 
GSM538353 
GSM538354 
proB.FrA.BM#1 
proB.FrA.BM#4 
proB.FrA.BM#5 
proB.FrA.BM#8 
Fraction B/C FrBC GSM538418 
GSM476671 
GSM399450 
proB.FrBC.BM#4 
proB.FrBC.BM#2 
proB.FrBC.BM#1 
Fraction Cʹ FrC GSM476669 
GSM399452 
GSM399453 
preB.FrC.BM#1 
preB.FrC.BM#2 
preB.FrC.BM#3 
Fraction D FrD GSM476670 
GSM399448 
GSM399449 
preB.FrD.BM#3 
preB.FrD.BM#1 
preB.FrD.BM#2 
Fraction E FrE GSM476652 
GSM399438 
GSM399439 
B.FrE.BM#1 
B.FrE.BM#2 
B.FrE.BM#3 
Fraction F FrF GSM476653 
GSM399440 
GSM399441 
B.FrF.BM#1 
B.FrF.BM#2 
B.FrF.BM#3 
Transitional Stage 1 T1 GSM538213 
GSM538214 
GSM538215 
B.T1.Sp#1 
B.T1.Sp#2 
B.T1.Sp#3 
Plasma Cell PC GSM538198 
GSM538199 
GSM538200 
B.Fo.PC#1 
B.Fo.PC#2 
B.Fo.PC#3 
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environment. The annotated R scripts used for all microarray analyses can be found in 
Appendix A. 
 
2.4.2 Fractions A, Cʹ and F Differentially Expressed Genes. 
Hardy fractions A, Cʹ and F were used to identify a preliminary list of candidate 
genes that were differentially expressed during B cell development in bone marrow. 
Using the Biobase (65) and Oligo (67) packages and the pd.mogene1.1 annotation file 
(68), the arrays were background corrected and normalized using the Robust Multi-Array 
Average (RMA) method (69). Differentially expressed genes were identified using the 
Limma (70) and Affycoretools packages (71).  
 
2.4.3 Differentially Expressed Gene Clustering 
Microarray data from bone marrow B cell development stages and several non-
immature B cell development stages (Table 2.2) were normalized and background 
corrected as described in section 2.4.2. The features were annotated using the online 
Clone|Gene ID converter (72). The edited annotated text file was imported into Genesis 
1.7.6 (73). A principle component analysis (PCA) was performed to determine how 
closely the technical microarray replicates correspond with one another and to identify 
potential batch effects in the arrays. The 35,556 features were filtered using the 3759 
features identified to be differentially expressed between Fractions A, Cʹ and F. 
Unsupervised, mutual-information or Euclidian average-linkage clustering was performed 
using the Genesis program defaults for each setting. 
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2.4.4 Network Analysis and Biological Annotation  
A subset of the 38 CD24 co-clustered genes was used to define a gene network 
interaction map. Using the online GeneMANIA tool (74) the gene network map was 
generated using published data from Homo sapiens or Mus musculus after confirming the 
38 genes were orthologous. GeneMANIA selected annotation sources according to 
program defaults. 144 data sources were selected as: 20 co-expression, 2 co-localization, 
3 genetic interaction, 6 pathway, 61 physical interaction, 50 predicted and 2 shared 
protein domain sources. The number of GeneMANIA-supplied genes was set to a 
maximum of 20. To identify the largest possible network from available data, genes from 
the cluster were added sequentially in the order given by Genesis in the hierarchical 
cluster. If a gene disrupted the network established in the previous iteration, it was 
excluded until no more genes could be added without disrupting the established network. 
Nineteen co-clustered genes could be successfully mapped into a network. Caspase 7 was 
also included, based on previously published data linking CD24 and Caspase 7 (58) 
bringing the total number of user-supplied genes to 20. Thus, the final network contained 
20 genes from the CD24 cluster and 20 known interacting genes from GeneMANIA, 
which were then manually annotated. The Database for Annotation, Visualization and 
Integrated Discovery (DAVID) online tool  (75, 76) was used to identify Gene Ontology 
(GO) enrichments in the network.  
 
2.5 Bone Marrow B Cell Isolation 
Femurs were removed from euthanized male C57/BL6 mice (3-6 weeks of age) 
and bone marrow was flushed out with Quin saline (QS, 25 mM NaHEPES, 125 mM 
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NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM Na2HPO4, 0.5 mM MgSO4, 1 g/L glucose, 2mM 
Glutamine, 1 mM Sodium pyruvate, 50 µM 2-Mercaptoethanol, pH 7.2), using a 21-gauge 
needle. Single-cell suspensions were produced by sieving cells through a 100 m nylon 
mesh. The EasySep Mouse B Cell Enrichment kit (Cat. #19754) or the EasySep Mouse B 
Cell Isolation Kit (Cat. #19854) from StemCell Technologies (Vancouver, BC) were used 
to enrich bone marrow isolates by removing non-B cells (Table 2.3) following the 
manufacturer’s protocol. Fc-receptors were blocked on the B cells using anti-mouse 
CD16/CD43 (FcγIII/II receptor). 
 
2.6 Analysis of Cell Death 
Primary immature B cells were isolated using StemCell B cell Isolation Kit 
#19854 (StemCell Technologies, Vancouver, BC) and were plated in flat bottom tissue 
culture plates at a density of 5x105 cells/mL in RPMI complete medium and were left 
untreated or treated with 10 g/mL of M1/69 rat-anti-mouse antiCD24 or matched 
isotype control antibody in the presence or absence of 5 ug/mL goat-anti-rat secondary 
antibody. Cells were incubated for 24 h at 37C and 5% CO2. After 24 h, cells clusters 
were photographed under light microscope. Cells were assessed for apoptosis by FACS 
analysis by staining with AnnexinV-Alexa488 and Propidium Iodide (PI) using the Dead 
Cell Apoptosis kit (Cat. V13241) from Invitrogen, following the manufacturer’s protocol. 
Briefly, 5x105 cells were washed once in ice-cold PBS. Cells were resuspended in 100 
L, 1X Annexin-binding buffer (50 mM HEPES, 700 mM NaCl, 12.5 mM CaCl2, pH 
7.4) containing 5 L Alexa Fluor 488 Annexin V and 1L of 100 g/mL PI and 
incubated for 15 minutes at room temperature in the dark. Annexin-binding
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Table 2.3: Components of the Mouse B cell Isolation Cocktail from StemCell 
Technologies’ Mouse B Cell Isolation Kit (19854).  
 
a Protein targets of antibodies in the selection cocktail. 
b Cell targets of selection cocktail antibodies. 
 
 
 
Protein Targeta Cellular Targetb 
CD4 CD4+ T cells, macrophages and granulocytes 
CD8a CD8+ T cells 
CD11b Macrophages, neutrophils, monocytes, granulocytes, NK cells 
CD43 Thymocytes, T cells, Fraction A/B/C pro-B cells, Monocytes, 
Granulocytes 
CD49b Platelets 
CD90.2 Pan T cell marker 
Ly-6C/G (Gr-1) Monocytes, Neutrophils, Macrophages, Endothelial cells, 
CD8+ T-cells, Hematopoietic Cells 
TER119 Erythrocytes 
CD16/CD32 Fcγ III/II Receptor 
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buffer (400 μL) was added to the cells, which were kept at 4C in the dark until analyzed 
by flow cytometry. In parallel, B cell enrichment was determined via analysis of CD19 
expression by washing cells three times in FACS buffer (PBS with 1% heat-inactivated 
FBS), then stained anti-mouse CD19 antibody in 100 L FACS buffer, followed by three 
additional washes in FACS buffer. Cells were kept at 4C in the dark until flow analysis. 
Flow cytometry data were collected on a FACSCalibur flow cytometer (BD Biosciences, 
San Jose, CA.) using CellQuest Pro V4.0.2 software (BD Biosciences, San Jose, CA.). 
Analysis of the results was performed using FlowJo v10.0.5 (Tree Star, Ashland, OR.) 
 
2.7 Analysis of Endocytosis 
C57BL/6 mice were sacrificed and immature bone marrow-derived B cells were 
isolated using B cell isolation kit 19854 as described in section 2.5. Enriched immature B 
cells (5x105 cells) were resuspended in 0.5 ml QS and rested at 37C prior to antibody 
treatment. M1/69 or isotype control Ab (10 g) and biotinylated goat-anti-rat secondary 
Ab (5 g) in 0.5 mL of QS were pre-incubated at room temperature at least 30 min. Cells 
and the pre-mixed Abs were incubated for 1, 5, 15, 40 or 60 min at 37˚C, as indicated. 
The untreated control sample was incubated with 1 mL of QS for 60 min at 37˚C. Cells 
were then transferred to 3 mL of ice-cold FACS buffer to halt endocytosis. Cells were left 
on ice in the presence of pre-mixed Abs for a minimum of 10 min to ensure that the Ab 
had sufficient time to bind to surface CD24. The untreated control sample was incubated 
with the pre-mixed Abs for 30 min on ice. Cells were then washed 3 times in FACS 
buffer followed by incubation with 0.25 g of streptavidin-FITC, 0.125 g of anti-mouse 
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CD19-PerCP-Cy5.5 or both in 100 L of FACS buffer for 30 minutes at 4C in the dark. 
Cells were then washed three times in FACS buffer followed by resuspension in 1% 
paraformaldehyde in FACS buffer.  
To determine if the actin cytoskeleton dynamics were involved in CD24 
endocytosis, cells were pre-treated with 1 µM of the F-actin destabilizing agent 
cytochalasin D (cytoD) dissolved in Dimethyl sulfoxide (DMSO) or DMSO alone as a 
vehicle control for 30 minutes prior to antibody addition. Cells were analyzed using the 
BD FACSCalibur and data analysis done using FlowJo v10.0.5 (Tree Star, Ashland, OR.) 
 
2.8 Analysis of CD24 Localization 
C57BL/6 mice were sacrificed and immature bone marrow-derived B cells were 
isolated using B cell isolation kit 19854 as described in section 2.5. Enriched immature B 
cells (5x105 cells) were treated as previously described to induce endocytosis, 10g 
M1/69 or isotype control Ab pre-incubated with 5 g of Biotinylated goat-anti-rat 
secondary antibody in 0.5 ml QS for a total volume of 1 ml in the presence or absence of 
DMSO and Cytochalasin D as described in section 2.7. Plasma membrane-bound CD24 
was stained using 0.5 µg Streptavidin-FITC per 5x105 cells. Cells were fixed in 3.7% 
paraformaldehyde. Fixed cells were spun onto glass slides using a Shandon Cytospinner 
centrifuge (Thermo Scientific, Waltham, MA) for 5 min at 1600 x g. Cells were mounted 
in VectaShield hardset mounting media with 4',6-diamidino-2-phenylindole (DAPI) 
(Vector Labs, Burlingame, CA). Confocal imaging was done using the Olympus FV1000 
system and IX81 inverted microscope (Olympus, Shinjuku, Japan) and FV10-ASW (ver 
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3.1) software. Imaging was performed using Laser diode (405 nm), and Argon laser (488 
nm) with DAPI and FITC bandpass filters. Imaging was done at 40X optical 
magnification, with digital magnification between 1.5 and 2.9x. Images were taken at 
20.0 µs/pixel with sequential excitation of the fluorophores by line.  
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CHAPTER 3: RESULTS 
3.1 CD24 mRNA expression is not dynamic in WEHI-231. 
3.1.1 Induction of Growth Arrest and Differentiation in WEHI-231 cells. 
WEHI-231 is an IgM+, CD24+ mouse immature B lymphoma cell line thatwas 
first assessed as a model to examine the regulation of CD24 mRNA expression. CD24 
expression is known to decrease when naive B-cells differentiate into antibody-secreting 
plasma cells. Conditions to stimulate the same differentiation in the WEHI-231 cell line 
were therefore first established in vitro. In vivo, B cells will normally differentiate into 
plasma cells upon stimulation of the BCR by exogenous antigens via antigen presenting 
cells (such as CD4+ helper T cells or dendritic cells) and the CD40 co-receptor through 
interaction with CD40L. In vitro, this is mimicked using anti-IgM and anti-CD40 
antibodies. Stimulation with anti-IgM alone will cause growth arrest and apoptosis in 
IgM+ immature B cells, while stimulation with anti-CD40 alone will not alter cell 
survival or differentiation. Stimulation with both anti-IgM and anti-CD40 will, however, 
induce proliferation and maturation in IgM+ immature B cells. A second method to 
stimulate maturation is through activation of Toll-like receptors (TLR) via Escherichia 
coli-derived lipopolysaccharide (62). 
To determine the optimal antibody concentration to induce anti-IgM-mediated cell 
death and anti-IgM/anti-CD40 proliferation, 3.125x105 or 6.25x105 cells/mL were 
stimulated with varying concentrations of anti-IgM and anti-CD40 antibody for 24h 
(Table 2.1). Cellular viability was then assessed using the MTT assay, which measures 
active metabolism through the reduction of a soluble, yellow tetrazolium dye (MTT) to an 
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insoluble purple formazan precipitate. At 3.12x105 cells/mL, cell viability maximally 
reduced with 200 ng/mL of anti-IgM. While increasing concentrations of anti-CD40 were 
capable of partially restoring cell viability it was not rescued to control levels (Fig. 3.1A). 
At 6.25x105 cells/mL, treatment with 400 ng/mL anti-IgM produced reduced cell viability 
to a minimum, at 32% of control while 800 ng/mL anti-CD40 co-stimulation was 
sufficient to restore cell viability to the same level as control (Fig. 3.1B). Therefore, it 
was decided that WEHI-231 at 6.25x105 cells/mL would be treated with 400 ng/mL of 
anti-IgM and 800 ng/mL of anti-CD40 to examine what effect this has on the expression 
of CD24.  
 
3.1.2 CD24 expression is unaffected in stimulated WEHI-231 cells 
The mRNA expression level of CD24 was measured by RT-PCR 6 or 24 h after 
treatment with anti-IgM and/or anti-CD40 (Fig. 3.2). There were no observable changes 
to CD24 mRNA levels in response to either anti-IgM or anti-CD40 treatment or to the 
combination at either 6 h or 24 h. Treatment of WEHI-231 cells with 3 µg/mL of LPS has 
been shown to induce differentiation and maturation (62) and thus CD24 expression was 
also examined after LPS treatment. Cells were also treated with LPS alone or in 
conjunction with anti-IgM and anti-CD40 to determine if CD24 expression was regulated 
in WEHI-231 cells upon differentiation into plasma cells. Similar to the findings with 
anti-IgM and anti-CD40, no changes in CD24 expression were observed (Fig. 3.3). These 
results were confirmed by flow cytometry, which also showed no changes in surface 
protein levels (data not shown). Therefore, WEHI-231 cells do not recapitulate the 
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Fig. 3.1: MTT assay to determine anti-IgM/anti-CD40 concentrations required to induce 
growth arrest and rescue. Control is RPMI-completed media without the addition of anti-
IgM or anti-CD40 antibody. A. Antibody stimulation in 2.5x104 cells at 3.125x105 
cells/mL. B. Antibody stimulation in 5.0x104 cells at 6.25x105 cells/mL. n=1 with two 
technical replicates. Values for antibody concentrations informed the optimal treatment 
conditions in subsequent WEHI-231 experiments.  
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Fig. 3.2: Expression of CD24 mRNA is not affected by antibodies to induce B cell 
differentiation and activation. WEHI-231 cells were left untreated (Untr), treated with 
400 ng/mL anti-IgM  (αIgM), treated with 800 ng/mL anti-CD40 or with both anti-IgM 
and anti-CD40 anti-IgM+anti-CD40 for A. 6h or B. 24h. mRNA was isolated and CD24 
expression determined by RT-PCR. RPLPO expression was also determined and used as 
a loading control. Representative result of 4 independent biological replicates. Both the 
time points are from the same experiment. 
 
 
 
 
 
Results 
 40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3: Expression of CD24 mRNA is not affected by LPS stimulation in WEHI-231. 
Untr is untreated, IgM is 400 ng/mL anti-IgM treatment, LPS is 3.0 g/mL of LPS and 
LPS+anti-IgM+anti-CD40 is co-treatment with LPS, anti-IgM/anti-CD40. A. 6h of 
treatment B. 24h of treatment. CD24 expression was compared against RPLPO as a 
housekeeping gene. RNA integrity was poor in the LPS/IgM/CD40-treated 24h sample. 
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changes in CD24 expression in response to maturation observed in primary B cells and 
are not an appropriate model for investigating the regulation of CD24 expression. 
Consequently, all further work used primary B cells. 
 
3.2 Bioinformatics-based Identification of Potential CD24 Interactors 
3.2.1 Differentially Expressed Genes from Early to Late B-cell Development 
Microarray data generated by the Immunological Genome Project was used to 
identify genes whose expression mirrors that of CD24 through B-cell development in 
bone marrow. The first analysis focused on Hardy fractions A, Cʹ and F since these 
fractions are CD24-, CD24+ and CD24-, respectively, to identify genes whose expression 
was broadly similar to that of CD24. In total, 3759 unique features were differentially 
expressed (p<0.005). To identify genes with similar expression to CD24 over the entire 
bone marrow development process, these 3759 genes were analyzed in each Hardy 
fraction, splenic-derived Transitional B cells and Plasma cells. A Principle Component 
Analysis revealed that replicates for each of these data sets clustered with the exception of 
Fractions F and Plasma Cells (Fig. 3.4) and the data were free of batch effects. 
 
3.2.2 Hierarchical Clustering, Network Analysis and Biological Annotation of CD24 Co-
expressed Genes 
To identify genes that share the closest expression to CD24, unsupervised 
hierarchical clustering was performed on the 3759 genes identified above (Fig. 3.5). The 
analysis revealed several distinct groups of gene expression across B cell development 
(Fig. 3.5A). CD24 resided in a unit of genes that are highly expressed during the late pro- 
Results 
 42 
 
Fig. 3.4: Principle Component Analysis (PCA) of microarray data. Biological replicates 
are circled. Replicates form distinct clusters with the exception of Hardy Fraction F and 
Plasma Cells (FrF and PC), which are intermingled. FrA is Hardy fraction A, FrB/C are 
Hardy fraction B or C cells, FrCʹ is Hardy fraction Cʹ, FrD is Hardy fraction D, FrE is 
Hardy fraction E, FrF is Hardy fraction F. T1 are Transitional stage 1 B cells, MLP are 
Multi-lineage Progenitor Stem cells and PC are Peritoneal Plasma Cells. 
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Fig. 3.5: Hierarchical clustering of differentially expressed (DE) genes during B cell 
development. The total number of DE genes and control features was 3759. Yellow 
denotes higher expression and blue indicates lower expression. A. Clustering of all DE 
genes. Boxes outline major ‘groups’ of co-expressed genes. B. 55 features representing 
38 genes co-expressed with CD24.  
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to early pre- B cell developmental phases, and may be expressed again during splenic 
maturation. From this, a CD24 co-cluster was identified that contained the features that 
most closely match CD24’s expression (Fig. 3.5B). This cluster contained 55 features, 
corresponding to 38 individual genes (Table 3.1).  
A network interaction map was generated using 19 CD24 co-clustered genes. The 
full list of 38 genes could not be analyzed due to a lack of published interaction data 
among them. The 19 selected genes represented those which could form the largest 
interaction network. Additionally, Caspase 7 was added as it was previously shown to 
respond to CD24 signalling (58). GeneMANIA-suggested a further 20 genes which 
interacted heavily with the provided CD24 co-clustered genes according to program 
defaults (Table 3.2) (74). The addition of the GeneMANIA suggested genes allowed a 
more complete network interaction map to be generated by identifying potential indirect 
interactions between the CD24 co-clustered genes. GeneMANIA networked genes 
according to the following parameters: Co-expression; co-localization; genetic 
interactions; pathway interactions; physical interactions; predicted interactions and shared 
protein domains. Due to the larger volume of published data, a more complete network 
could be constructed using data from Homo sapiens (Fig. 3.6) than Mus musculus. Prior 
to assessing the biological functions of these genes, it was first established that all 40 of 
the genes share significant ontology between the two species and that they perform 
analogous functions  
Gene ontology (GO) annotation was used to assign biological significance to the 
list of 40-networked genes. Using GO, genes are categorized into three hierarchies: 
biological processes (BP), molecular functions (MF) and cellular components (CC).  
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Table 3.1: Thirty-eight genes clustering with CD24 identified via unsupervised 
hierarchical clustering.  
 
 
a Official gene symbols and names are taken from The Mouse Genome Informatics 
Database (http://www.informatics.jax.org/mgihome/nomen/) as set by the International 
Committee on Standardized Genetic Nomenclature for Mice.  
Official Gene Symbola Gene Name 
SPEF2 Sperm flagellar 2 
CSRP2 Cysteine and glycine-rich protein 2 
RABL5 RAB, member RAS oncogene family-like 5 
EGFL6 EGF-like-domain, multiple 6 
EHD2 EH-domain containing 2 
MCF2L MCF.2 cell line derived transforming sequence-like 
CD24 CD24 molecule 
MARCKS Myristoylated alanine-rich protein kinase C substrate 
MYL4 Myosin, light chain 4, alkali; atrial, embryonic 
HSPA2 Heat shock 70kDa protein 2 
ZNF382 Zinc finger protein 382 
MYEF2 Myelin expression factor 2 
HDAC5 Histone deacetylase 5 
PRELID1 PRELI domain containing 1 
DNAJC21 DnaJ (Hsp40) homolog, subfamily C, member 21 
PREP Prolyl endopeptidase 
FCHO1 FCH domain only 1 
BAP1 BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase) 
BTBD10 BTB (POZ) domain containing 10 
PTGR1 Prostaglandin Reductase 1 
ELOF1 Elongation factor 1 homolog (S. cerevisiae) 
COQ7 Coenzyme Q7 homolog, ubiquinone (yeast) 
THBD Thrombomodulin 
UCHL1 Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 
GPAM Glycerol-3-phosphate acyltransferase, mitochondrial 
PLA2G12A Phospholipase A2, group XIIA 
BCL2L1 BCL2-like 1 
AP1AR Adaptor-related protein complex 1 associated regulatory protein 
DCK Deoxycytidine kinase 
P2RX3 Purinergic receptor P2X, ligand-gated ion channel, 3 
CAPSL Calcyphosine-like 
GFRA1 GDNF family receptor alpha 1 
TIFA TRAF-interacting protein with a forkhead-associated domain 
SMARCA4 
SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
GPR12 G protein-coupled receptor 12 
DDC Dopa decarboxylase (aromatic L-amino acid decarboxylase) 
TRIM2 Tripartite motif-containing 2 
IRS1 Insulin receptor substrate 1 
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Table 3.2: Forty Genes used to perform network and gene ontology enrichment analysis.  
 
Official Gene Symbola Gene Name 
SPEF2b  Sperm flagellar 2 
AP1AR  Adaptor-related protein complex 1 associated regulatory protein 
RABL5  RAB, member RAS oncogene family-like 5 
TIFA  TRAF-interacting protein with a forkhead-associated domain 
PLA2G12A  Phospholipase A2, group XIIA 
COQ7  Coenzyme Q7 homolog, ubiquinone (yeast) 
ELOF1  Elongation factor 1 homolog (S. cerevisiae) 
GPAM  Glycerol-3-phosphate acyltransferase, mitochondrial 
CD24 (CD24A) CD24 molecule 
MCF2L  MCF.2 cell line derived transforming sequence-like 
FCHO1  FCH domain only 1 
EGFL6  EGF-like-domain, multiple 6 
EHD2  EH-domain containing 2 
BTBD10  BTB (POZ) domain containing 10 
MYEF2  Myelin expression factor 2 
MARCKS  Myristoylated alanine-rich protein kinase C substrate 
UCHL1  Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 
HSPA2  Heat shock 70kDa protein 2 
BCL2L1  BCL2-like 1 
CASP7c Caspase 7, apoptosis-related cysteine peptidase 
MTMR2d Myotubularin related protein 2 
C5orf22  Chromosome 5 open reading frame 22 
TSR1  TSR1, 20S rRNA accumulation, homolog (S. cerevisiae) 
HSPBP1  Hsp70-interacting protein 
TARDBP  TAR DNA binding protein 
DLG5  Discs, large homolog 5 (Drosophila) 
MYOF  Myoferlin 
BCL2L11  BCL2-like 11 (apoptosis facilitator) 
BIK  BCL2-interacting killer (apoptosis-inducing) 
PLA2G12B  Phospholipase A2, group XIIB 
MARCKSL1  MARCKS-like 1 
DYX1C1  Dyslexia Susceptibility 1 Candidate 1 
ESD  Esterase D/formylglutathione hydrolase 
SH3GL2  SH3-domain GRB2-like 2 
TIFAB  TIFA-related protein TIFAB 
CCDC14  Coiled-coil domain containing 14 
EHBP1  EH domain binding protein 1 
MEOX2  Mesenchyme homeobox 2 
BAK1  BCL2-antagonist/killer 1 
NEDD8  Neural precursor cell expressed, developmentally down-regulated 8 
a Official gene symbols and names are taken from The Mouse Genome Informatics 
Database (http://www.informatics.jax.org/mgihome/nomen/) as set by the International 
Committee on Standardized Genetic Nomenclature for Mice. 
b Highlighted in grey are genes derived from the CD24 co-expression cluster.  
c Highlighted in black is Caspase 7 which was included due to its known association with 
CD24-mediated signalling.  
d GeneMANIA suggested genes.   
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Fig. 3.6: Network analysis of 40 CD24 associated genes using GeneMANIA. Coloured 
boxes indicate the genes that participate in the same pathway or function. Capase-7 is 
highlighted with * to indicate it was not a clustered gene. Lines represent known 
associations between genes and are colour coded based on the type of interaction as 
shown in the legend. Line thickness represents the relative weight associated with that 
association to the network. Twenty genes (black circles) are co-clustered with CD24 
expression during B cell development. 20 genes (grey circles) were selected by 
GeneMANIA
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The categories are further organized by parent and child relationships whereby each 
hierarchy is subdivided into increasingly specific descriptors. For example, BP includes 
cell death, followed by programmed cell death, followed by apoptosis. The list of 40-
networked genes was assessed using the online Database for Annotation, Visualization 
and Integrated Discovery (DAVID) tool (75, 76) to determine if there were significant 
enrichments in any specific ontology. Significant enrichment was found in mitochondrial 
apoptotic signalling (p =3.1x10-5), and several related subfamilies. In addition, both the 
ontologies Endocytosis (p=0.076) and Src-Homology (SH3) Domain-containing proteins 
(p=0.074) trended towards significant enrichment. Various sub-functions in apoptosis, 
membrane organization and several other gene ontologies were also noted (Appendix B). 
Manual biological annotation provided additional support that several genes not identified 
by DAVID participate in mediating apoptosis, endocytosis or in general cytoskeletal 
organization. Therefore, the network generated by the GeneMANIA analysis was 
manually annotated to highlight the main functions of mitochondrial apoptosis, 
endocytosis and cytoskeletal organization (Fig. 3.6). The MCF.2 Cell Line Derived 
Transforming Sequence-like (MCF2L) GTPase is included in the endocytosis category 
since it is known to regulate endocytosis (77) even though it is not closely networked 
with the other endocytosis genes. Furthermore, both CD24 and caspase-7 are highlighted 
for clarity. 
As the DAVID software is limited to specific source data to establish ontology 
enrichments, the list of genes was also manually annotated using PubMed to identify any 
functions or associations that were not identified electronically. DAVID initially 
identified CD24, Eps Homology 15 Domain Containing-2 (EHD2) and SH3-Domain 
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Containing, Growth Factor Receptor Bound Protein-Like 2 (SH3GL2) as participating in, 
or being associated with, endocytosis. While EHD2 and SH3GL2 are both known 
endocytosis genes (78, 79) CD24 has not been directly associated with endocytosis in 
previously published literature. Electronic analysis of CD24 suggested it may participate 
in endocytosis due to its similarity to other genes (Inferred from Electronic Annotation), 
and it has been shown to interact with proteins like Src which can modulate vesicle 
trafficking (29) Subsequent manual annotation identified a further 4 genes that are also 
associated with various functions in vesicle trafficking and the regulation of endocytosis: 
Adapter-Related Protein Complex 1 Associated Regulatory Protein (AP1AR), FCH 
Domain Only-1 (FCHO1), Rab-Like 5 (RabL5), MCF2L and Heat Shock Protein 2 
(HSPA2) (77, 80-83). Therefore, combining the results from DAVID as well as the 
manual curation revealed that 8 of the 19 CD24 co-clustered genes are known to be 
involved in regulating endocytosis or vesicular transport. Based on these findings, we 
hypothesize that CD24 is associated with endocytosis in immature B cells. 
 
3.3 Magnetic Enrichment of Bone Marrow B Cells 
To functionally validate this hypothesis and determine if CD24 is associated with 
endocytosis, primary mouse ex-vivo B cells isolated from bone marrow were used. 
Untouched magnetic separation was used to purify non-stimulated B cells from bone 
marrow. The two magnetic separation kits that were available from StemCell 
Technologies for untouched magnetic separation were the mouse B cell enrichment kit 
(catalogue number 19754) and the mouse B cell isolation kit (19854). As both kits were 
designed to isolate B cells from splenic tissue, it was first necessary to determine if they 
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were also able to enrich developing B cells from the bone marrow.  Analysis of the 
populations recovered after isolation revealed that results with the B cell enrichment kit 
(19754) were highly variable and only provided a 45.6% pure population of B cells with a 
standard error rate of 6.4% (n=6). By comparison, results with the B cell isolation kit 
(19854) averaged 89.6% CD19+ B cells with a standard error of 0.96% over 21 isolations 
(Tables 3.3 and 3.4). It was therefore determined that the Mouse B cell enrichment kit 
(19754) was unsuitable for isolating B cells from bone marrow, but that the B cell 
isolation kit (19854) was well adapted for this role. All subsequent B cell isolations thus 
relied on this kit.  
The relative abundance of B cell fractions immediately following sacrifice, 
immediately after magnetic isolation using kit 19854, and also after 20 hours in tissue 
culture were assessed. Unenriched bone marrow had 24.6% B220+ cells and 21.1% 
CD19+ cells when labelled singly with their respective Abs (Fig. 3.7A and B). When 
expression of both B220 and CD19 was investigated by incubating with both Abs 
simultaneously, there was 32.0% (5.57% + 26.4%) B220+ cells and 26.6% (0.24% + 
26.4%) CD19+ cells (Fig. 3.7C). The increase in positive staining cells was potentially 
due to a slight interaction between the fluorophores, or natural variation in the biological 
samples. Overall, there were 26.4% B220+/CD19+ cells, representing Hardy fractions B 
through F. Of the B220+ cells, 17.4% were CD19- (Fig. 3.7C) representing Hardy 
fraction A. More than two thirds of the total cell population did not express either the 
B220 or CD19 B cell markers indicating a large number of non-B cells were present in 
the unenriched bone marrow. 
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Table 3.3: Comparison of the StemCell Technologies Mouse B cell Enrichment Kit 
(19754) and the Mouse B cell Isolation Kit (19854).to enrich B cells from bone marrow.  
 
StemCell  
Kit Cat. 
Number 
Date of 
experiment 
Mouse age 
(weeks) 
Number of 
Cells used in 
Magnetic 
Separation 
% Isolation 
from 
Unenriched 
Bone marrowa 
B cell purity 
by CD19 
expressionb 
19754 25 Oct 12 3.5 weeks 1.00x10
8 57.5% 23.9% 
19754 06 Nov 12 5 weeks 1.00x10
8 32.5% 30.5% 
19754 22 Nov 12 3 weeks 1.00x10
8 20.0% 48.3% 
19754 26 Nov 12 4 weeks 1.00x10
8 35.25% 65.3% 
19754 28 Nov 12 4 weeks 1.00x10
8 26.50% 49.0% 
19754 03 Dec 12 3 weeks 1.00x10
8 22.75% 56.8% 
19854 12 Dec 12 3.5 weeks 1.00x10
8 33.0% 85.5% 
19854 17 Dec 12 3 weeks 1.00x10
8 27.5% 80.0% 
19854 19 Dec 12 4 weeks 1.50x108 18.0% 90.4% 
19854 16 Jan 13 3 weeks 8.0x10
7 15.5% 84.3% 
19854 21 Jan 13 4 weeks 8.0x10
7 22.0% 91.8% 
19854 23 Jan 13 4 weeks 8.0x10
7 22.5% 91.8% 
19854 04 Feb 13 2 weeks n.d. n.d. 84.4% 
19854 08 Feb 13 3 weeks 8.725x107 26.1% 88.5% 
19854 12 Feb 13 5 weeks 6.775x107 24.0% 92.4% 
19854 13 Feb 13 5 weeks 77x1067 25.8% 92.4% 
19854 22 Feb 13 6 weeks 9.54x107 17.6% 83.5% 
19854 26 Feb 13 5 weeks 90x1067 20.9% 89.0% 
19854 27 Feb 13 5 weeks 5.49x107 32.3% 90.7% 
19854 5 Mar 13 6 weeks 8.0x107 28.8% 85.5% 
19854 7 Mar 13 6 weeks 6.27x107 21.2% 90.4% 
19854 17 Mar 13 3 weeks 6.19x107 21.3% 90.2% 
19854 26 Mar 13 4 weeks 8.0x107 26.9% 94.3% 
19854 15 Apr 13 7 weeks 8.0x107 15.3% 91.3% 
19854 23 Apr 13 4 weeks 9.38x107 19.2% 96.0% 
19854 25 Apr 13 4 weeks 8.0x107 25.0% 91.5% 
19854 30 Apr 13 5 weeks 9.3x107 23.0% 98.0% 
a % Isolation from unenriched bone marrow is the number of isolated cells from total 
bone marrow cells used. 
b B cells were identified by their expression of CD19 as assessed by FACS. 
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Table 3.4: Summary of B cell enrichment using the StemCell Technologies B Cell 
Enrichment Kit (19754) and the B cell Isolation Kit (19854). 
 
Kit Average CD19+ St. Deviation St. Error Variance n 
19754 45.6% 15.7% 6.4% 2.5% 6 
19854 89.6% 4.4% 0.96% 0.19% 21 
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Fig. 3.7: Isolation of B cells from mouse bone marrow using untouched magnetic 
separation. Unenriched bone marrow (A, B and C) was compared with magnetically 
isolated B cells either uncultured (D, E and F) or cultured for 20h in RPMI complete 
media (G, H, and I). B cell isolates. B220 and CD19 expression were used to determine 
B cell purity. Lineage committed B cells belonging to Hardy fractions B-F express both 
CD19 and B220 and are identified in C, F and I in the upper-right quadrant. 
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The induction of apoptosis required B cells to be cultured in tissue media for 
varying times. To determine how overnight incubation may affect the isolated B cells, the 
relative populations of B220 and CD19+ cells were assessed immediately after isolation, 
and after 20 hours in tissue culture. Immediately after isolation, a substantial number of 
non-B cells were successfully removed with 91.5% of the cells expressing B220 and 
90.7% expressing CD19 (Fig. 3.7D and E). When cells were co-labelled with anti-B220 
and anti-CD19, there were 96.6% (3.36% + 93.2%) B220+ cells and 94.2% (1.03% + 
93.2%) CD19+ cells (Fig. 3.7F). The cell population contained 93.2% B220+/CD19+ 
cells indicating they were Hardy Fractions B through F. In the B220+ cell population, 
3.5% of the cells were CD19- (Fig. 3.7F), representing Hardy fraction A. The total non-B 
cells were substantially reduced to less than 4%. 
After 20 h in culture there were 87.3% B220+ cells and 84.3% CD19+ cells (Fig. 
3.7G and H). When co-labelled with both anti-B220 and anti-CD19 Abs there were 
87.6% (7.63% + 80.0%) B220+ cells and 81.3% (1.34% + 80.0%) CD19+ cells (Fig. 
3.7I). The cell population contained 80.0% B220+/CD19+ cells representing Hardy 
fractions B through F. Of the B220+ cell population, 8.7% did not express CD19 and 
were thus Hardy fraction A cells. There were 11.1% B220-/CD19- non-B cells. As B cells 
are not viable for long-term culture without growth factor supplementation and co-
culturing with stromal cells, this change in population distribution was likely due to the 
loss of cells in the culture. Overall, the results demonstrated that the magnetic isolation kit 
19854 was well suited to the isolation of immature bone marrow B cells and that these 
isolated cells were able to be cultured for short periods in RMPI 1640 complete media. 
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3.4 Antibody Crosslinking of CD24 Induces Apoptosis in Primary B Cells. 
Next, antibody clustering experiments were performed on the isolated, enriched B 
cells ex vivo to determine if clustering of CD24 induces apoptosis in primary developing 
B cells. After incubation with antibody for 24 hours, B cell cultures were assessed for the 
proportion of apoptotic verses viable cells. Apoptosis was measured using FITC-labelled 
AnnexinV and Propidium Iodide (PI) co-staining. B cells in early apoptosis are positive 
for AnnexinV, but negative for PI whereas those in late apoptosis are both AnnexinV+ 
and PI+. Cells undergoing non-apoptotic or necrotic cell death are AnnexinV- but PI+. 
An average of 28.03% of control-treated samples were apoptotic, with 20.5% of those 
cells early apoptotic, and 79.5% of cells late apoptotic (Fig. 3.8). Treatment with M1/69 
anti-CD24 in the absence of secondary antibody showed a slight, but non-significant 
increase in apoptotic cells compared with isotype. However, treatment with M1/69 and 
anti-M1/69 secondary antibodies to cluster CD24 resulted in a significant increase in the 
number of apoptotic cells (while no significant changes in necrosis were noted). On 
average, 59.5% of cells were apoptotic, with 35.5% early apoptotic and 64.5% late 
apoptotic. These results conclusively demonstrated that antibody crosslinking of CD24 
induces apoptosis in primary B cells ex vivo.  
 
3.5 Surface Expression of CD24 is Dynamically altered in response to Antibody-
mediated Clustering 
3.5.1 CD24 is rapidly externalized prior to endocytosis 
The results from the bioinformatics analysis suggested that CD24 could be 
associated with endocytosis. To determine if CD24 is endocytosed in response to 
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Fig. 3.8: Antibody mediated crosslinking of CD24 causes significant increases in 
apoptosis in bone marrow-derived, immature ex vivo B cells. Cells were incubated for 
24h after addition of M1/69 anti-CD24 antibody or the isotype control antibody in the 
presence or absence of secondary antibody. Apoptosis was determined via Annexin V-
FITC and Propidium Iodide staining. Statistical significance was determined using a 
paired Students’ t-test. n=3 **p<0.005. A. Average induction of apoptosis (n=4). B. 
Representitive experiment showing proportion of early vs. late apoptotic cells. 
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Results 
 58 
antibody crosslinking and clustering, the expression of CD24 protein on the cell surface 
was examined. B cells were incubated with pre-mixed M1/69 anti-CD24 and a 
biotinylated anti-M1/69 secondary antibody for 1 to 60 minutes at 37˚C along with 
untreated control samples which were incubated for 60 minutes at 37˚C without antibody 
addition. Only biotinylated Ab remaining on the cell surface could bind streptavidin-
FITC, and thus, only surface CD24 is detected. Unexpectedly, there was a significant 
increase in CD24 surface expression from 0 to 15 minutes followed by a decrease in cell 
surface expression (Fig. 3.9).  
To determine if the changes to surface CD24 expression were statistically 
significant, the number of cells in each log unit of fluorescence intensity was analyzed at 
each time point (Fig. 3.10A and B). After 60 minutes at 37˚C, untreated control samples 
had an average of 93% of cells expressed CD24 (as indicated by relative fluorescence 
intensity above 101). Additionally, there was no change in the fluorescent intensity 
between untreated control samples and those incubated with antibody for 1 min In 
untreated control samples the largest population, with 62.7% of the total cells at this time 
point, had a fluorescent intensity between 102 and 103 and 2.6% had fluorescence above 
103. Within 15 minutes of Ab-mediated crosslinking, there was a substantial change in the 
population distribution of CD24 expression. At this time, the number of cells with 
fluorescence intensity between 103 and 104, increased significantly from 2.6% to 34.8%. 
A total of 53.6% of the cells had a fluorescence intensity between 101 and 103. At this 
time, however, an increase in the population of cells lacking CD24 surface expression 
appeared, as 11.6% of the cells fell below 101. By 60 minutes, the number of cells with a 
fluorescence intensity below 101 increased significantly from 3.04% at 5 minutes 
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Fig. 3.9: CD24 surface expression is dynamic after antibody crosslinking in bone 
marrow-derived, immature ex vivo B cells. Cells were incubated for the indicated times in 
M1/69 anti-CD24 antibody in the presence of biotinylated secondary antibody. CD24 was 
stained with streptavidin-FITC for FACS analysis. Vertical line indicates modal CD24 
expression of the control sample. Bins are demarked as 1 log unit of fluorescence 
intensity. Representative results shown from n=4 replicates. 
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Fig. 3.10: A. CD24 surface expression after antibody crosslinking. Fluorescence intensity 
was binned over four log units: blue, 0-10; red, 10-100; green, 100-1000; purple, 1000-
10000. Untr is untreated control sample. B. Heat map of all significant changes in CD24 
expression across the four bins of fluorescent intensity. Significance was determined 
using a 1-way ANOVA followed by a TukeyHSD post-hoc analysis. n=4 
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to 35.0%. At both 40 and 60 minutes, however, 15.7% and 13.8% of cells, respectively, 
retained higher levels of CD24 on the cell surface with fluorescence above 103. As this 
method is specific for surface CD24 rather than total cell, or intracellular protein, the 
CD24-negative fraction represented cells that had lost CD24 surface expression at these 
time points. These results conclusively demonstrated that in response to antibody-
mediated crosslinking of CD24, B cells rapidly externalized large amounts of CD24 
protein followed by an equally rapid loss of surface expression. 
In this experiment, a loss of fluorescent intensity may have been caused by 
receptor internalization via endocytosis, or by shedding of the receptor from the surface. 
To determine if CD24 protein was lost from the surface due to endocytosis or receptor 
shedding, primary and biotinylated secondary antibodies were pre-mixed with FITC-
labelled streptavidin and added to isolated B cells for 30 minutes on ice before the 37C 
incubation. This resulted in all cell surface CD24 being FITC-labelled thus allowing 
detection of both surface and any subsequently internalized CD24, but not CD24 that had 
been shed. CD24 staining increased over the entire 60-minute time course. This can be 
explained through the increased amount of CD24 expressed on the cell surface during the 
first 15 minutes of antibody crosslinking. As unbound antibody was not removed prior to 
incubation at 37C, any newly externalized CD24 would also be FITC-labelled prior to 
internalization thus the overall fluorescence increased over time. This confirmed that the 
loss of surface staining was due to endocytosis rather than receptor shedding since the 
signal was not lost (Fig. 3.11). Furthermore, this result confirmed that the amount of 
surface CD24 protein increased in response to antibody clustering.  
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Fig. 3.11: CD24 is internalized and not shed following antibody crosslinking in bone 
marrow-derived immature ex vivo B cells. CD24 was pre-stained with M1/69 and FITC-
labelled secondary antibody  for 30 minutes on ice prior to incubation at 37C for the 
indicated times, which will detect total surface and internalized CD24. CD24 expression 
was normalized to 1 minute. Increasing protein expression was detected over the course 
of 1h. n=4. 
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3.5.2 CD24 internalization is enhanced by actin depolymerisation 
Dynamic actin rearrangement is known to be required for internalization of GPI-
linked proteins through receptor-mediated endocytosis (84). To determine if CD24 
endocytosis is actin-dependent, cells were pre-treating with Cytochalasin D (CytoD) for 
30 minutes before antibody addition. CytoD-mediated loss of actin dynamics did not 
impair the internalization of CD24 (Fig. 3.12). At 40 minutes, an average of 48% of cells 
had florescence intensity at 101 or lower, indicating a loss of CD24 surface protein. 
Surprisingly, there was a greater loss of CD24 in CytoD treated cells compared to control 
treated cells (21.8%), although this difference only trended towards statistically 
significant (P=0.07). This suggests the dynamics of CD24 surface expression are 
influenced by actin cytoskeleton depolymerisation. 
 
3.6 CD24 Localization Changes in Response to Antibody Crosslinking 
3.6.1 Antibody crosslinking induces dynamic rearrangement of CD24 localization 
Confocal microscopy was used to determine if the distribution of CD24 on the cell 
surface changed during antibody crosslinking (Fig. 3.13). Cell samples were taken during 
the endocytosis assay previously described. In untreated control samples, CD24 staining 
was punctate, with several well-defined foci and no obvious polarity. Within 5 minutes of 
antibody addition, however, cells began to become polarized with respect to CD24 
distribution on the cell surface. Cells lost the punctate foci and developed unilateral or 
bilateral poles of CD24 expression. In this 5-minute interval, substantially larger areas of 
the cell stained for CD24, as demonstrated by the comparison between the small foci in 
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Fig. 3.12: Changes in surface CD24 expression after Cytochalasin D pre-treatment in 
response to antibody cross-linking. Cells were incubated with antibody for 40 minutes at 
37C. Statistical significance was assessed using a Paired Student’s t-test. 
*=P<0.05, +=P<0.1. n=3 
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Fig. 3.13: Confocal microscopy analysis of CD24 expression and localization in non-
interacting, single B cells in response to antibody crosslinking. Surface CD24 was stained 
with FITC (green) and cell nuclei were stained with DAPI (blue). Representative images 
of 3 experiments. Scale bar is 30 µM.  
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the untreated control sample and the larger ‘crescent’ at 5 minutes. Cell polarization was 
also more pronounced at 5 minutes, where the majority of cells had a unipolar expression 
of CD24. By 15 min, CD24 polarity was maintained and there was an increase in the 
membrane coverage of surface CD24 expression in single cells, while some developed 
membrane ruffling. The appearance of a broader pattern of surface staining for CD24 is 
consistent with the increased protein expression quantified by FACS (Fig. 3.9). In 
addition, within 15 minutes, two distinct cell phenotypes were observed with a portion of 
cells forming clusters and others remaining as non-interacting single cells.  
At 40 and 60 minutes, single cells lost most, if not all, of their surface CD24 expression 
(Fig. 3.13). At 40 minutes, single cells returned to a mostly punctate staining, where 
many cells had only a single area of expression, or lost CD24 expression entirely. By 60 
minutes, single cells were predominantly CD24- with very few retaining any measureable 
expression. These results support the FACS data, as flow cytometry only records the 
fluorescence of single cells, and any clusters would be disrupted immediately prior to 
analysis or not analyzed by the software. These data were also congruent with the results 
from the endocytosis assay, which showed a significant reduction in cells expressing 
surface CD24, but a small proportion of cells retaining high levels of surface protein.  
With respect to each time point, CD24 staining in cell clusters was more intense 
than in non-interacting single cells and large portions of the cell surface became CD24+ 
in these clusters (Fig. 3.14). In clustered cells CD24 was localized on the membrane faces 
between interacting cells after 40 min of anti-CD24 clustering. By 60 min, there was a 
reduction of staining in clusters. CD24 expression was found on a large fraction of the 
cell surface in these clustered cells that were present on the interior of clusters,
Results 
 67 
 
 
Fig. 3.14: Confocal microscopy analysis of CD24 expression and localization in clustered 
B cells in response to antibody crosslinking. CD24 was stained with FITC (green) and 
cell nuclei were stained with DAPI (blue). Representative images of 3 experiments. Scale 
bar is 30 µM. 
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however in many cases there was reduced or absent expression on the external face of the 
outermost cells of the cluster. As described in section 3.5.2, treatment of cells with CytoD 
tended to increase the internalization of CD24 in B cells. Confocal microscopy was also 
used to determine how it affected the distribution of CD24 on the cell surface (Fig. 3.15). 
Cells treated with DMSO as the vehicle control responded similarly to cells treated with 
anti-CD24 alone: clusters had the highest level of CD24 expression, and single cells had 
predominately punctate staining with no obvious localization. In comparison, CytoD 
treated cells had a profound loss of CD24 expression both in single cells and in cells 
found in clusters (Fig. 3.15). Remarkably, no single cells were found to express CD24 in 
the images obtained. Even in clusters, CD24 expression was only detected in a minority 
of cells indicating that CytoD treatment results in an increase in the rate of endocytosis.  
These results supported the hypothesis that CD24 is not acting as the anchor for 
cell adhesion, but is mediating these interactions by regulating other cell adhesion 
proteins. Furthermore, the CytoD data show that CD24 expression is not permanently 
maintained in cell clusters. In cells not treated with CytoD the CD24 retained in clusters 
after it has been lost in single cells is likely due to a change in the rate of endocytosis or 
exocytosis rather than the abrogation of the process. The results from both the FACS and 
confocal analysis strongly suggest that altering actin dynamics profoundly augments 
CD24-mediated endocytosis; however, the precise role of the actin cytoskeleton in 
regulating this process is unclear. 
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Fig. 3.15: Confocal microscopy analysis of CD24 expression and localization in non-
interacting, single B cells pre-treated with DMSO or 1 µM Cytochalasin D in response to 
antibody crosslinking. CD24 was stained with FITC (green) and cell nuclei were stained 
with DAPI (blue). Representative images of 3 experiments. Scale bar is 30 µM. 
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CHAPTER 4: DISCUSSION 
4.1 Summary 
The purpose of this investigation was to determine if WEHI-231 cells are an 
appropriate model system to examine CD24 gene regulation in B cells and to determine  a 
mechanism through which CD24 induces apoptosis in bone marrow-derived, immature B 
cells. Using a bioinformatics-based approach, I identified co-regulated genes to be 
essential regulators of endocytosis, vesicle trafficking and cytoskeletal organization. 
From this I hypothesized that engagement of CD24 is associated with endocytosis, and I 
have shown, for the first time, that primary mouse B cells, isolated from bone marrow 
using untouched magnetic separation, are susceptible to CD24-induced apoptosis. Using 
this model, I have shown that CD24 surface expression is dynamic in response to 
antibody crosslinking, with an initial increase in surface expression followed by 
endocytosis of CD24. In addition, I have also demonstrated that CD24 protein 
accumulates in localized membrane regions and is a mediator of homotypic cell adhesion. 
 
4.2 Many transformed B cells do not model CD24 biology  
Past studies of CD24 function and regulation in B cells have either used 
transgenic or knockout animals (56, 57), transformed cell lines (46, 58) or an in vitro 
long-term cell culture system from bone marrow B cells (19). As a first attempt to follow 
CD24 expression upon B cell activation in vivo, the expression in the mouse B cell line 
WEHI-231 was characterized. WEHI-231 cells are classified as an immature (Hardy 
fraction E) malignant B cell lymphoma (62). Previously it was reported that these cells 
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are resistant to CD24-mediated apoptosis (19) and indeed, I found that CD24 expression 
is not dynamically regulated in response to maturation stimulation in WEHI-231 cells. As 
such, I conclude that both the regulation of CD24 expression and the regulation of 
downstream function in these cells is deregulated.  
The classification of WEHI-231 cells as immature B cells is derived from their 
high expression of the B-cell receptor in the IgM isoform (62). In normal B cells, CD24 
expression is significantly reduced in this fraction (2, 3), whereas WEHI-231 cells 
express CD24 at high levels more analogous to the pre-B cell Hardy fractions. Indeed, 
recent research has shown that WEHI-231 cells have characteristics that belong to several 
different B cell stages. In a recent bioinformatics analysis, it was found that they share 
similar gene expression patterns to pre-B cells (Hardy fraction Cʹ or D) (85), while other 
research has suggested that they are more analogous to mature, transitional B cells or a 
nonconventional mature B cell (86). This incongruity strongly suggests that WEHI-231 
cells may not be truly representative of normally developing B cells and may explain why 
the underlying system regulating the expression of CD24 appears to be dysfunctional.  
In addition to WEHI-231, other immature B cell lines have been developed using 
both human and mouse systems. The response of these other cell lines to CD24 
crosslinking is largely unknown. Research has been done using the human Burkitt’s 
lymphoma lines P32/SH and Namalwa, as well as the Pre-B HPB-NULL, NALM-6, 
NALM-17 and P30/OHK and the Pro-B NALM-16, NALM-20, NALM-27, LC4-1 and 
KM-3 cell lines, which demonstrated CD24 crosslinking induces apoptosis in these 
human cells (46, 56, 58). Thus, other mouse or human cell lines such as CH31 and B104, 
respectively could be used to investigate the activity of CD24. 
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Despite their inability to model CD24 activity, the malignant transformation in 
WEHI-231 cells that renders them insensitive to CD24-mediated apoptosis may serve to 
help identify potential signalling partners or pathways that can alter a cell’s 
responsiveness to CD24. WEHI-231 cells are resistant to CD24, but they retain their 
sensitivity to other apoptosis-inducing signals, such as crosslinking of the BCR (85, 86), 
demonstrating that the underlying apoptotic machinery is still functional in these cells. As 
the underlying biological transformation that generated the WEHI-231 lymphoma is not 
known, identifying the disrupted processes would provide insight into the pathways 
required for CD24 activity. It has been noted that other transformed B cells are also 
resistant to CD24 mediated apoptosis as well (19); thus any future research into 
classifying the nature of their transformations can also inform future CD24 research.  
One well-documented transformation, which renders B cells insensitive to CD24-
mediated apoptosis, is the Abelson transformation (19).  Abelson-transformed cell lines 
have been infected with the Abelson murine leukemia virus (87, 88). This virus encodes 
the v-Abl gene, which shares a high degree of similarity to the mammalian c-Abl gene 
(87, 88). The result is a constitutively active form of the Abl non-receptor tyrosine kinase 
(88). This transformation is also similar to a mutation in humans called the Philadelphia 
chromosome, caused by a reciprocal translocation between the Breakpoint Cluster Region 
gene and the c-Abl gene creating constitutively active BCR-Abl fusion protein (89). 
In both cases, the malignant transformation is mediated through the Abl tyrosine 
kinase, which interacts with members of the Ras superfamily of proteins, such as Rho 
GTPases RAC1 and CDC42 (90, 91). These proteins are known to regulate processes 
such as cell cycle control, vesicle trafficking, cytoskeletal arrangement and cell polarity 
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(92, 93). Furthermore, the microarray analysis has shown positive correlations between 
CD24 expression and several members of the Ras superfamily of proteins. For example, 
one of the most similar genes with regard to CD24 expression is the Rho GTPase 
regulator MCF2L that mediates endocytosis, and interacts with both Rac1 and CDC42 
(94). CD24 expression is also positively correlated with other GTPase proteins such as 
the previously discussed RabL5, RHOT2, which regulates mitochondria and apoptosis 
(95), and a CDC42 regulator involved in cell shape modification (CDC42EP3; CDC42 
Effector Protein 3) (96). Thus, the bioinformatics data in conjunction with our knowledge 
of the WEHI-231 cell line suggest that the induction of apoptosis by CD24 is dependent 
on members of Ras superfamily. These data are further supported in that Lyn, a Src 
family tyrosine kinase which was previously discussed to be downstream of CD24 
signalling, is upstream of both CDC42 and RAC1 in B cell receptor signalling (97).  
From these results, we can conclude that the WEHI-231 cell line is unsuitable for 
further research with regard to endogenous CD24 activity in healthy, immature B cells. In 
the future WEHI-231, as well as other transformed B cell lines, could serve as a model 
system to identify the molecular mechanism for the resistance of transformed cells to 
undergo CD24-mediated apoptosis. 
 
4.3 Generation of hypothesis that CD24 is associated with endocytosis by 
bioinformatics analysis 
In recent years microarray analysis, and other bioinformatics tools, have produced 
large caches of gene expression data. Furthermore, the establishment of the MIAME 
(Minimum Information About Microarray Experiments) protocol ensures that data from 
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DNA microarray studies are made freely available to the research community. ImmGen is 
a MIAME-compliant research collaboration that is mapping the transcriptomes of 
immune relevant cells, including each stage of B cell development.  
This valuable resource has allowed the exploration of the relationships between B 
cell development and CD24 expression to identify potential partners for CD24 function. 
Specifically, data from the ImmGen database were used as a hypothesis-generating tool 
using the “guilt by association” theory (98). “Guilt by association” postulates that in 
biological systems, genes which share similar expression patterns, either through time or 
under a selection system, are more likely to be involved in the same, or congruent 
processes, and potentially be under the same transcriptional control (98). While this type 
of analysis is limited to correlative association, it can suggest previously unknown protein 
partners or processes for further study. In effect, this technique is used as a screen to 
select potentially relevant genes from the background population. Individually, the genes 
may provide targets that can be functionally validated, but this can be time consuming, 
particularly with large numbers of genes, as each target must be validated individually. 
Furthermore, many pathways have multiple redundancies, which increase the potential for 
false negative or false positive results at the functional level. By comparison, grouping 
genes into functional clusters based on functional relatedness allows biological processes 
to be validated instead. For example, the screen of ImmGen data revealed EHD2, FCHO1 
and RABL5 (among others) as participating in endocytic vesicle formation and 
trafficking. Blocking or enhancing endocytosis rather than targeting each gene separately 
can achieve functional validation.  
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The “guilt-by-association” technique is particularly relevant in identifying 
underlying gene expression regulatory factors, isolating functional relatedness in poorly 
understood proteins or pathways, and is used extensively in pharmaceutical target 
identification. For example, Smith et al. (99) used this approach followed by loss-of-
function analysis to identify regulatory elements controlling cytokinesis via central 
spindle proteins. “Guilt by association” was also used to predict the function of heart 
tissue-enriched mitochondrial genes Coiled-coil-helix-coiled-coil-helix domain 
containing 10 (CHCHD10) and glioblastoma amplified sequence (GBAS) (100). Little 
was known about the function of these genes, but associations suggested they were 
involved in oxidative phosphorylation, which was later validated (100). Finally Lounkine 
et al. (101) used “guilt by association” to identify potential side effects from drug testing 
by identifying pathways which may be affected outside of the intended clinical 
application. In that study, 656 drugs were studied, and 73 off-target side effects were 
postulated. The authors noted that half of these were subsequently confirmed in clinical 
data (101). Moving beyond gene expression and network analysis, this approach provided 
testable hypotheses through gene ontology enrichment. 
In this thesis, potential CD24 partners were identified using unsupervised 
clustering followed by biological annotation and network analysis. Thirty-eight co-
expressed genes were identified out of over 35,000 genes analyzed. The subsequent 
network analysis and the identification of gene ontology enrichments identified that the 
three major processes that correlated with CD24 expression to be: mitochondrial 
apoptosis and apoptotic signalling; cytoskeletal organization; and endocytosis and vesicle 
trafficking. Identification of endocytosis as a process associated with CD24 formed the 
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basis of the major hypothesis of this thesis, which is that CD24 signalling is associated 
with endocytosis. The data presented in this thesis fully support this hypothesis, however, 
the precise endocytic process through which CD24 is internalized has yet to be 
established. 
The genes whose expression clusters with CD24 expression may provide targets 
for loss-of-function or gain-of-function studies to determine how the identified genes 
specifically contribute to CD24 function. For example, EHD2, one of the closest of the 
co-clustered genes to the expression of CD24, is involved in mediating vesicle 
internalisation (79). Small Interfering RNA knockdown of EHD2 has been demonstrated 
in 3T3-L1 mouse adipocytes to disrupt endocytosis (79) and thus represents a valid target 
in mouse B cells. If disruption of EHD2 also inhibits CD24 endocytosis, it would be 
strong evidence that CD24 is internalized via a similar process. Alternatively, genes 
identified in our network could inform target choices to restore sensitivity to CD24-
mediated apoptosis, such as in WEHI-231 cells.  
 
4.4 Induction of apoptosis by CD24 clustering in bone marrow derived B cells ex-
vivo 
To functionally validate the microarray analysis, an ex vivo model system for 
studying CD24-functionality in immature, bone marrow-derived B cells was first 
developed. As previously mentioned, prior research on CD24 expression in B cells has 
used a variety of cell lines, in vitro tissue culturing, transgenic and knockout animals (9, 
19, 46, 56, 58). While these systems have provided vital insight for the role of CD24 in B 
cell survival, they cannot replicate the innate in vivo biology of immature B cells since 
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genetically altered mice are able to compensate for loss or gain-of-function of CD24, and 
cell lines or long-term culture methods can change the inherent response of cells. By 
using untouched magnetic separation, we are able to isolate normal, functional B cells 
with normal levels of endogenous CD24.  
Using bone marrow derived B cells, it was clear that endogenous CD24 induces 
cell death in wild-type, immature B cells expressing endogenous levels of receptor. The 
induction of apoptosis requires extensive crosslinking of CD24 on the cell surface, as 
evidenced by the need for a secondary antibody to induce significant cell death. Previous 
in vitro studies using mouse pro- and pre-B cells co-cultured with bone marrow stromal 
cells, as well as human Burkitt’s and Acute Lymphoblastic Leukemia cells, demonstrated 
that addition of primary anti-CD24 antibodies could induce apoptosis, but that adding 
secondary antibodies to further cluster the receptors increased apoptosis significantly, but 
was not absolutely required (19, 58, 60). This is in disagreement with the results 
presented here, which showed that primary antibody alone was not sufficient to induce 
apoptosis, but that secondary antibody clustering was required. In the study by Chappel et 
al. (19), the efficacy of apoptosis induction by primary antibody alone was compared to 
the combined primary/secondary antibody treatments in mouse B-cells derived from bone 
marrow cell cultures. Their results indicated that primary antibody alone could induce 
apoptosis and the presence of a secondary antibody potentiated this effect (19). The 
ability of primary antibody alone to induce apoptosis may be due the amount of CD24 
expression the cell surface following this culturing, or possibly due to phenotypic changes 
in the B cells during the prolonged cell culture. Comparatively, our experiments use B 
cells directly isolated form bone marrow without tissue culture. Furthermore, Chappel et 
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al. (19) made extensive use of co-culturing with stromal cells to support B cell 
populations, which provides a different microenvironment from using a more 
homogenous isolated population. Subsequent studies in human cell lines, most notably 
with HPB-Null Pre-B cell acute lymphoblastic leukemia cells used the combined primary 
and secondary antibody treatment exclusively to induce apoptosis (58). Fundamentally, 
however, our results as well as the results from both of these previous studies (19, 58) 
strongly suggest that multiple CD24 receptors must be clustered in order to efficiently 
activate intracellular activation of pro-apoptotic pathways.   
 It is also important to note our results have demonstrated that the respond to 
CD24 crosslinking is specific and requires CD24 to be engaged, and is not a result of 
either Fc receptor-mediated action or non-specific antibody binding. B-cells express 
receptors that can bind the constant region of antibodies (Fc receptors), which can 
modulate immune cell responses (102). During B-cell isolation anti-Fc receptor 
antibodies were added, which block the ability of these receptors to bind the anti-CD24 or 
secondary antibodies used to engage CD24. Furthermore, the response to CD24 Ab-
mediated crosslinking absolutely requires anti-CD24 antibody because cells incubated 
with matching isotype antibody with the same secondary antibody did not undergo 
increased cell death or endocytosis. 
The observation that a high level of CD24 clustering is necessary to induce cell 
death by CD24 is consistent with studies on other lipid raft-associated, GPI-linked 
proteins. For example, lipid raft clustering brings multiple CD59 proteins into close 
proximity and initiates downstream signalling (84). This clustering has been shown to 
recruit between three and nine receptors and leads to the downstream activation of the 
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Lyn kinase (103). Another example is the GPI-linked urokinase plasminogen activator 
receptor (uPAR). In human melanoma cells, evidence suggests that uPAR clustering is 
required for efficient activation and that the receptors will cluster in caveolin-coated 
invaginations prior to endocytosis (104).  
As previously discussed the microenvironment of the bone marrow is critically 
important in B cell development and thus may play a role in CD24-mediated behaviour in 
pre- and pro-B cells. Immature B cells are dependent on bone marrow stromal cells for 
much of their early development (2, 48, 49). Multiple stromal cell lines are available and 
can mimic the normal stroma in this regard. Thus, our ex vivo system can be modified by 
culturing stromal cells with the immature B cells to determine if the microenvironment of 
the bone marrow modifies the response to CD24. Another consideration in replicating the 
bone marrow microenvironment is that the various cell populations produce and require 
different growth factors and cytokines to support hematopoietic cell development. For 
example, early B cells are critically dependent on the hematopoetic growth factor IL-7 
(50, 52) and the production of Stromal Cell-Derived Factor (SDF-1), also known as 
CXCL12, which directs pro-B cell chemotaxis and promotes appropriate stromal 
attachment (105). CXCL12 is chemotactic for lymphocytes such as B cells. Of further 
interest, the receptor for this factor is CXCR4, whose function is negatively regulated by 
CD24 (105). The CXCL12/CXCR4 signalling system is a major regulator in B cell 
development and directs the earliest B cell precursors to areas capable of supporting their 
development (106). Thus, a promising avenue for future studies is to examine how the 
bone marrow microenvironment influences CD24 function and vice versa. 
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In addition to their support from bone marrow stromal cells, B cell development is 
highly dependent on the contextual interactions of early B cells with each other (107, 
108). For example, research has shown that pre-B cells stimulate maturation through 
homotypic contact through stimulation of the pre-B cell receptor and that blocking these 
interactions induces maturation arrest (108). Our results have conclusively shown that 
CD24 activation causes the rapid formation of B cell clusters, so it is reasonable to 
conclude that CD24 may be a regulator of these homotypic interactions. Indeed, a second 
opportunity with this ex vivo system is to further isolate and then selectively combine 
specific B cell populations (for instance, Pro-B cell, Hardy fraction Cʹ and Pre-B cell, 
Hardy fraction D cells) to determine what effect, if any, the local B cell populations have 
on each other.  
 
4.5 Dynamics of CD24 Surface Expression  
This is the first report showing that surface expression of CD24 is dynamic in 
response to antibody crosslinking. In addition, this work is the first to suggest a 
mechanism through which CD24 can initiate signalling since CD24 has no 
transmembrane domain. Previous research has demonstrated that other GPI-linked 
receptors are endocytosed after crosslinking (84) and that endocytic vesicles can affect 
intracellular signalling pathways via the endosomal adapter proteins on their surface 
(109-111). For example, the Eps15 protein, which participates in both clathrin and non-
clathrin mediated endocytosis also regulates B cell lymphopoiesis (110). Endosomal coat 
proteins have also been shown to activate MAPK proteins such as Erk1/2 from endocytic 
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vesicles (109), which are the same downstream targets of CD24. Thus, endocytosis 
represents a plausible intial signalling event following CD24 stimulation. 
Endocytosis can be divided into two major categories: Clathrin-dependent 
endocytosis (associated with traditional Receptor-Mediated endocytosis), and 
caveolin/lipid raft-mediated endocytosis (112, 113). Each process requires unique 
mediator proteins and results in different downstream events. First isolated in 1975, 
clathrin is a triskelion-shaped protein, which forms a scaffold around the nascent 
endocytic vesicles, or endosomes (114, 115). At the plasma membrane, the process of 
clathrin-mediated endocytosis (CME) can be subdivided into three stages: 1) the 
formation of the clathrin coat; 2) the invagination of the plasma membrane and; 3) the 
release of the coated vesicle from the membrane surface (114). The formation of the 
clathrin coat begins when adapter proteins, such as AP-2, recruit clathrin to the plasma 
membrane in response to surface receptor signalling (111, 114). The nucleation of 
clathrin at the membrane then causes invaginations to form (111). During this process, a 
host of regulatory proteins including, but not limited to, Eps15, Intersectin, Epsin and 
amphiphysin can bind to the nascent vesicle (111). Finally, scission proteins, such as 
dynamin release the vesicle from the membrane (111, 114). Research suggests that the 
initial adapter protein, such as Adapter Protein-2 (AP-2), and the subsequent regulatory 
proteins are variable and that the specific association of different proteins can direct 
downstream consequences including signalling from the clathrin coated vesicle, or the 
trafficking of the endosome (111, 114).  
Clathrin-mediated endocytosis was synonymous with receptor-mediated 
endocytosis signalling for many years (114) and was viewed as a mechanism to resolve or 
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attenuate a signalling event by the internalization and either degradation or recycling of 
the receptor (111). However, it has been shown that these endosomes can recruit cytosolic 
factors and act as signalling platforms (111). For example, clathrin-dependent receptor 
mediated endocytosis of Receptor Tyrosine Kinases (RTKs) can activate ERK1/2 from 
endosomes (111). This has been found to be the case for signalling from the Epidermal 
Growth Factor Receptor (EGFR), the Insulin Receptor and the Neurotrophin receptor 
(TrkA) and appears to be common to RTKs in general (116). This parallels research 
showing that CD24 is associated with the protein tyrosine kinase Lyn and can also result 
in activation of ERK (46). Interestingly, the results from the bioinformatics analysis show 
that CD24 is co-expressed with mediators of clathrin-dependent endocytosis, such as 
adaptor-related protein complex 1 associated regulatory protein (AP1AR) (81) and 
FCHO1 (80).  
 Lipid raft-mediated endocytosis is another mechanism for endocytosis. In some 
cases caveolin proteins induce endocytosis by coating membrane invaginations, termed 
caveolae (113). The nature of lipid raft-mediated endocytosis is complicated in lymphoid 
cells, including B cells, as they do not express caveolin (117), but can form functional 
caveolae-like invaginations from clustered lipid rafts in a cholesterol-dependent manner 
(84). Caveolin-coated and lipid raft-derived caveolae retain the same physical and 
functional properties (113). As such, it is becoming increasingly common to discuss 
caveolin/lipid raft endocytosis as one type of endocytosis (113). Caveolin appears to be a 
vesicle-stabilizing protein that delays the scission of the vesicle from the membrane 
(113). One theory is that caveolin creates a stabilized signalling platform whereas the 
lipid rafts are used as a more rapid, transitional signalling system (113, 118). Indeed, 
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research has shown that caveolin itself is dispensable for endocytosis as the endocytosis 
of cholera toxin B by the ganglioside GM1 receptor can occur in the presence or absence 
of the caveolin protein (119).  
The release of endosomes from the plasma membrane into the cytoplasm, a 
process known as vesicle scission, is the next step in endocytosis. The protein dynamin, 
or dynamin-family proteins, are essential for scission, regardless if the endosomes have 
formed through clathrin- or caveolin/lipid raft-mediated events (113). Dynamin is a 
GTPase, which acts as a scission motor to release the endosome after it has formed (113). 
Thus, regardless of how cargo is targeted for endocytosis, the action of dynamin, or a 
closely related protein, is essential for any downstream internalization (113, 120). As 
such, we may hypothesize that despite lacking caveolin, GPI-linked receptors may still be 
endocytosed by lymphocytes through lipid raft-mediated invaginations followed by a 
release from the membrane by dynamin.  
Research in B cells on the GPI-linked CD59 cell surface receptor may serve as a 
model for the action of CD24 (84). CD59 is a known negative regulator of the 
compliment membrane attack complex (121). Like CD24, CD59 endocytosis was only 
observed after lipid raft clustering. Furthermore this internalization could be blocked 
using nystatin, a cholesterol-chelating agent that results in the disruption of lipid rafts (84) 
but clathrin-mediated endocytosis was unaffected (84). This strongly supports the 
contention that lipid rafts themselves can be mediators of endocytosis. Moreover, CD59 
was internalized through uncoated caveolae (84). Unlike what was observed for CD24, 
CD59 internalization was blocked when cells were treated with Cytochalasin H, an actin-
destablizing agent similar to CytoD (84). This suggests that dynamic actin rearrangement 
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is necessary for internalization of CD59, but that the inhibition of actin dynamics actually 
enhanced internalization of CD24. Another possibility is that the actin cytoskeleton is 
required to regulate the localization of CD24 on the cell surface, as well as its interactions 
with other surface proteins. Thus the addition of Cytochlasin D may disrupt these 
associations leading to the inappropriate or untimely internalization of CD24. 
Future work is necessary to determine the precise method by which CD24 is 
internalized. The results from our bioinformatics assay were the first to suggest that CD24 
may function through endocytosis. Several of the genes identified are involved in vesicle 
trafficking or serve as regulatory or adaptor proteins and are thus applicable to both 
clathrin and caveolin/lipd-raft –mediated endocytosis. Despite this, one of the genes with 
the closest co-expression pattern to CD24 is EHD2, which has recently been shown to be 
specific to caveolae internalization. Guilherme et al. (79) reported in 2004 that EHD2 
links endocytosis to the actin cytoskeleton. Subsequent research has shown that EHD2 
regulates endocytosis in a similar manner to caveolin, by delaying the release of caveolae 
from the cell surface into the cytosol. (122). Given the lack of caveolin expression in 
lymphocytes (117), it is possible that EHD2 may act as a substitute for caveolin function. 
As previously discussed, EHD2 knockdown has been accomplished in mouse cell lines 
opening the possibility for loss-of-function studies in isolated immature B cells. As such, 
understanding the role that EDH2 plays in mediating CD24 internalization is a priority for 
future studies.   
Future research could also use pharmacological inhibition of endocytosis to 
identify the mechanism for endocytosis of CD24 in B cells. There are several methods for 
selectively disrupting caveolin-, lipid raft-, and clathrin-mediated endocytosis. The first 
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hypothesis to test would be that CD24 is internalized via a lipid raft-mediated mechanism, 
given that other GPI-linked receptors are known to function in this manner and the co-
expression of CD24 and EHD2.  Inhibition of lipid-raft-mediated endocytosis has been 
accomplished using the cholesterol sequestering agents filipin or nystatin through 
selective depletion of cholesterol via methyl-β-cyclodextran, and by inhibiting cholesterol 
synthesis with enzymatic inhibitors (123).  
In addition to demonstrating that CD24 is endocytosed, this is the first study to 
observe that CD24 protein expression increases on the cell surface in response to 
antibody-mediated crosslinking. Moreover, this is the first time that CD24 has been 
implicated in regulating its own expression. The increase in CD24 protein may be due to 
either a rapid increase in the formation of new protein or due to the fusion of CD24-
containing exosomes with the plasma membrane. Further research is required to 
determine exactly how the increase in CD24 occurs. To help identify the mechanism, the 
level of expression of surface CD24 can be compared with the level of expression of 
internal CD24 that can be detected after membrane permeabilization followed by FACS 
and confocal analysis. If CD24 is pre-formed and resides in vesicles, it will be 
fluorescently labelled and thus detectable prior to exocytosis. Total cell staining would 
then show no increase over time whereas surface staining would increase. If CD24 is 
newly translated, however, both total cell and surface staining would increase during the 
first 15 minutes after antibody crosslinking. 
The regulation of CD24 surface expression is analogous to that of the glucose 
transporter type 4 (GLUT4) receptors. During signalling in response to insulin, GLUT4 
signals into the cell and is endocytosed from the cell surface. This initial signalling causes 
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the release of stored GLUT4 from pre-formed vesicles. In sustained signalling, the 
GLUT4 receptors are endocytosed and recycled to the surface to maintain signalling 
(124). 
The effect of CytoD on CD24 endocytosis has also raised new questions of the 
role that the actin cytoskeleton plays in regulating CD24 surface expression. CytoD 
disrupts actin dynamics by capping actin filaments, by preventing the addition of G-actin 
monomers, and by promoting the dissociation of filamentous actin (125). In clathrin-
dependent endocytosis, this serves to halt vesicle internalization (126). Indeed, the use of 
cytochalasin H was shown to block the endocytosis of CD59 in T cells. The original 
hypothesis was that CytoD would prevent CD24 internalization due to the loss of 
dynamic actin reorganization. Given the disparity between CD24 and CD59 endocytosis, 
it is likely that there are unknown roles for the actin cytoskeleton in mediating endocytic 
events from lipid rafts. Interestingly, when polarized endothelial cells are treated with 
CytoD, both clathrin-dependent and -independent endocytosis is inhibited from the apical 
membrane, but endocytosis from the basolateral membrane surface is enhanced (127, 
128). Given the appearance of a polar distribution of CD24 following stimulation, it is 
possible that the antibody-treated B cells become polarized and thus the rate of CD24 
endocytosis is increased from this face in response to CytoD. In order to fully validate the 
observed increase in CD24 endocytosis in the presence of a disorganized actin 
cytoskeleton, the cells would need to treateded with other inhibitors of actin dynamics, 
such as latrunculin A, which binds to monomeric actin (129), preventing it from forming 
filaments. If polymerized actin is required in mediating endocytosis, latrunculin A will 
inhibit internalization. Latrunculin A has been used to examine the relationship between 
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BCR signalling and the underlying actin network of B cells (59). After treatment with 
Latrunculin A, the B cell actin cytoskeleton was substantially disrupted and MAPK 
phosphorylation was induced, suggesting that cytoskeletal reorganization is a component 
of downstream signalling events following antigen recognition (59). 
 In addition to the change in overall surface expression, the distribution of CD24 
on the cell surface was also altered in response to antibody stimulation. Furthermore, 
there was a difference in the distribution of CD24 if B cells were non-interacting single 
cells or in clusters suggesting that the downstream effect of CD24 activation is dependent 
on the existence of cell-cell interactions. Within 5 minutes of stimulation, CD24 
distribution changes from punctate to highly organized and polarized. These polarized 
faces appear to serve as areas for cell to cell contact and indeed, within 40 minutes in 
interacting cells, CD24 expression appears to be intensified and is uniform around the cell 
membrane. Interestingly, over the same time course, CD24 expression is reduced or even 
completely lost in non-interacting cells. 
The confocal data further support the FACS analysis that demonstrated the 
endocytosis of CD24, but further suggested that single cells respond differently than cell 
clusters. As FACS analysis can only provide information on single cells and not clusters, 
we can thus be certain that CD24 is endocytosed rapidly from single cells, but that it may 
play other, as yet unknown, roles in cell clusters. Furthermore it is unknown if CD24 
expression is promoted or enhanced through clustering, or if clustering stabilizes CD24 
proteins at the cell surface, changes the rate of loss, or alters the balance between 
endocytosis and replacement at the cell surface. We may thus hypothesize that CD24 may 
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be important in establishing interactions between B cells and is lost in the event these cell 
to cell interactions are not established or maintained. 
Given its known role as a cell adhesion molecule (28), it may appear that 
following stimulation, CD24 is redirected to the cell surface to mediate the formation of 
these clusters; however the evidence that CD24 is endocytosed following crosslinking 
makes this unlikely. It is more likely that CD24-mediated signals cause changes in other 
cell adhesion molecules, which cause stable aggregates to form. CD24 has previously 
been shown to cause changes in pre-B cell adhesion through altering the VLA-4 adhesion 
molecule (42). In CD24+ cells, VLA-4 shows blockable binding to endothelioma cells 
with anti-VCAM-1 antibodies and it can bind to fibronectin. In CD24-/- cells, VLA-4 is 
unable to bind fibronectin and the binding to the same endothelioma cells cannot be 
blocked (42). This conclusively shows that CD24 mediates cell adhesion events without 
necessarily participating as the adhesion molecule itself. CD24 has also been shown to 
regulate Integrin β1 incorporation into lipid rafts and to promote tumour invasiveness in 
breast cancer cells (10). In both these examples, CD24 signalling is associated with 
changes in cell-cell adhesion, but through altering other adhesion molecules. The 
observation that CytoD results in a more rapid and pronounced loss of surface CD24 
compared with control treatments but that the cells do not lose their ability to cluster 
supports the hypothesis that the cell-cell adhesion is mediated by other receptors. If CD24 
was required for mediating this adhesion, CytoD would be disruptive. Instead, CytoD 
appears to alter CD24 expression and localization at later times without altering the cells’ 
ability to form clusters. These results also raise new questions for the role of CD24 in B 
cell development since it is unknown if these cell aggregates are related to the induction 
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of apoptosis, or if they are a secondary event. Therefore, future studies should determine 
if homotypic B cell adhesion is necessary for the induction of apoptosis. To do this, cells 
would be treated with antibodies against the cell adhesion molecule VLA-4. These 
antibodies would interfere with the ability of B cells to form clusters and thus could 
separate the induction of apoptosis from the formation of cell clusters to determine if 
these events are linked. 
While much of the mechanism remains unclear, the discovery that CD24 is 
endocytosed following receptor stimulation can now serve as a starting point for 
determining the precise signal transduction machinery responsible for inducing apoptosis 
and mediating B cell adhesion. 
 
4.6 Conclusions and Future Directions 
 The objectives of this thesis were to determine how cell surface CD24 expression 
may be regulated, and to identify a mechanism through which CD24 mediates apoptosis. 
To address these questions, a bioinformatics approach was used to identify potential 
protein partners in mediating CD24 activity through a ‘guilt-by-association’ approach. An 
ex vivo model was then developed to study CD24 biology in bone marrow derived B 
cells. Using this model, it was demonstrated that extensive clustering of CD24 is required 
to mediate apoptosis in B cells. Furthermore, it was shown that surface CD24 protein 
expression is dynamic and self-regulatory in response to antibody stimulation.  
In addition, the localization of CD24 was found to change in a highly coordinated 
fashion in response to antibody crosslinking. Prior to stimulation, CD24 resided in small, 
discrete foci distributed around the cell. After stimulation, CD24 surface expression 
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rapidly increased and became polarized. Interestingly, CD24 appears to have a context-
dependent expression pattern where single cells lose surface expression rapidly after 
polarization whereas interacting cells retain expression for a prolonged time. Finally, 
endocytosis of CD24 appears to be delayed by the presence of a dynamic actin 
cytoskeleton. 
 Taken together, these data along with published work suggest that clustering of 
CD24 results in a complex sequence of events culminating in apoptosis that can be 
delineated as follows:  
1. Extensive crosslinking via primary and secondary antibodies induces the protein 
of CD24 from small foci to larger membrane microdomains. These microdomains are 
increasingly pronounced at areas of cell-cell contact. 
2. CD24 crosslinking stimulates a rapid increase in the amount of protein on the cell 
surface, which is then followed by the endocytosis of the CD24 receptor. 
3. CD24 stimulates the formation of cell clusters. These cell clusters promote the 
retention of CD24 on the cell surface by decreasing the rate of endocytosis or 
recycling the CD24 protein back to the cell surface. Previously published data lend 
strong support to the suggestion that clustering occurs through other CAMs, such as 
VLA-4 or Integrin β1.  
4. Downstream signalling from CD24 induces apoptosis through alterations in 
mitochondrial function and the action of caspases. 
 
 Not only does this schema of CD24 activity correspond with our results, it is also 
applicable to the behaviour reported in the previously discussed studies. Furthermore, 
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several new avenues of research have been identified in response to this investigation. 
First, the rapid increase in CD24 surface expression in response to stimulation has not 
previously been shown. It is unknown if this increase is due to changes in CD24 
transcription and translation, or if it results from the mobilization of stored intracellular 
protein. Furthermore, if clustering of CD24 recruits sequestered vesicles, there is a strong 
possibility that other surface receptors or signalling molecules are co-recruited to the cell 
surface. Second, the mechanism through which CD24 mediates B cell adhesion is 
unknown. It is possible that CD24 itself is responsible for the formation of cell clusters; 
however, previous research (42) has shown that CD24 can induce changes in other cell 
adhesion molecules. It is unknown if endocytosis or cell-cell adhesion are linked to the 
mediation of apoptosis or if these outcomes are separate. Together, these data have 
identified likely mechanisms used to induce signalling by CD24 and have offered new 
insight and a new research pathway to explore the role that CD24 plays in B cell 
development. 
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CHAPTER 6: APPENDICES 
APPENDIX A: Annotated R Scripts 
# this is the process for creating a gene list to bring to Genesis 
# the genes_all.txt file is the full list of expressed genes 
# ttaallgenes is the full list of differentially expressed genes at set P.value (if coeff is 
undefined and n=10,000 to encompass all potential DE genes) 
 
setwd("C:/TinnR/acf_fractions") # set working directory for R session 
getwd() # confirm appropriate setting of w.d. 
source("http://bioconductor.org/biocLite.R")  #  to access Bioconductor packages if 
necessary 
biocLite("oligo")   # Oligo package is required during background correcting and 
normalization 
biocLite("pd.mogene.1.1.st.v1")  # The pd.mogene.1.1.st.v1 gene id file is the affymetrix 
platform design information for the MoGene 1.0ST gene array. 
 
NORMALIZING AND BACKGROUND CORRECTING 
 
library(Biobase)  # load libraries 
library(oligo) # load oligo 
library(pd.mogene.1.0.st.v1) # load platform design file 
celfiles=list.celfiles() # load CEL files 
celfiles # call back to confirm CEL files loaded 
data=read.celfiles(celfiles) # define data as the readout from the CEL files 
data # call back to confirm data is defined properly 
hist(data) # histogram plot of gene expression from CEL files (sequentially) 
boxplot(data) # boxplot of gene expression (sequentially) 
MAplot(data) # MAPlot of gene expression (sequentially) 
genes=rma(data, target="core") # define genes as the collected number of unique genes in 
the microarray by first collapsing any spots which match the same gene into a single 
function and then normalizing the array based on the RMA algorithm 
genes # confirm normalization and definition of genes 
hist(genes) # confirm normalization of arrays by histogram  
boxplot(genes) # boxplot of normalized gene expression 
MAplot(genes) # MA plot of normalized gene expression 
write.exprs(genes, file="genes_acf.txt") #for writing all genes in the microarray 
ExpressionSet data as a txt file.  
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IDENTIFYING DIFFERENTIALLY EXPRESSED GENES 
 
library(limma) # load the limma package 
library(affycoretools) # load the affycoretools package 
design=model.matrix(~0+factor(c(1,1,1,1,2,2,2,3,3,3))) # define the matrix of microarray 
data sets so that fraction A correspons to 1, fraction C’ corresponds to 2 and fraction F 
corresponds to 3. 
colnames(design)=c("FrA", "FrC", "FrF") # give column names to the matrix 
design # confirm the matrix design 
fit=lmFit(genes, design) # Perform a non-linear least squares fit on the genes according to 
the matrix 
contrast.matrix=makeContrasts(FrC-FrA, FrC-FrF, levels=design) # define the 
comparisons between fractions A, C’ and F 
contrast.matrix # confirm the contrast designs 
fit2=contrasts.fit(fit, contrast.matrix) # perform the contrasts 
fit3=eBayes(fit2) # statistical test on gene changes 
results=decideTests(fit3, p.value=0.005)  # only give a positive indication that genes are 
differentially expressed if they have an adjusted p. value of 0.005 or lower 
write.fit(fit3, results, "Maturation") # write the result into a file 
ttalldegenes=topTable(fit3, n=10000, adjust="fdr", p.value=0.005) # create a ranked top 
table of significant gene expression changes with a false discovery rate of 0.005 or lower 
# optional addition to top table; Coef 1/2= which comparison, ie: C-A=1 or C-F=2 
write.csv(ttalldegenes, file="genes_tt.csv")  # the Top Table is all differentially expressed 
genes, form All comparisons: ie: all Venn diagram segments between C-A and C-F 
 
######## 
 
The above procedure was performed two times. 
The first analysis was to identify differentially expressed genes from Hardy fractions A, 
C’ and F. The results were collected from the top table. 
 
The second use of R script was to create a normalized gene expression data set for 
Myeloid Progenitor Stem Cell (MLP), Hardy Fractions A through F, Splenic T1 cells and 
the Plasma Cell. This script only required use of the normalizing and background 
correcting scripts with the appropriate CEL files. 
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APPENDIX B: Gene Ontology Enrichment of CD24 Co-Clustered and GeneMANIA suggested genes by DAVID. 
 
Cell Death Signalling Enrichment Score: 1.953 
Term P-Value Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
Short sequence motif:BH3 
5.24E-06 
BAK1, BIK, BCL2L1, 
BCL2L11 
112.429 0.001 0.001 0.006 
Apoptosis regulator Bcl-2, 
BH 
1.27E-05 
BAK1, BIK, BCL2L1, 
BCL2L11 
84.136 0.001 0.001 0.014 
SM00337:BCL 
2.42E-05 
BAK1, BIK, BCL2L1, 
BCL2L11 
66.029 0.001 0.001 0.021 
Role of Mitochondria in 
Apoptotic Signalling 
3.06E-05 
BAK1, CASP7, BIK, BCL2L1 
43.545 0.000 0.000 0.021 
GO:0008637~apoptotic 
mitochondrial changes 
3.43E-05 
BAK1, CASP7, BCL2L1, 
CD24 
60.191 0.020 0.020 0.050 
GO:0008219~cell death 
5.16E-04 
BAK1, TARDBP, CASP7, 
BIK, BCL2L1, CD24, MCF2L, 
BCL2L11 
5.190 0.257 0.138 0.756 
GO:0016265~death 
5.38E-04 
BAK1, TARDBP, CASP7, 
BIK, BCL2L1, CD24, MCF2L, 
BCL2L11 
5.155 0.267 0.098 0.788 
GO:0005741~mitochondrial 
outer membrane 
6.94E-04 
BAK1, BCL2L1, GPAM, 
BCL2L11 
21.850 0.062 0.062 0.756 
GO:0005739~mitochondrion 
7.75E-04 
BAK1, HSPA2, CASP7, BIK, 
BCL2L1, COQ7, GPAM, 
MCF2L, BCL2L11 
4.070 0.069 0.035 0.844 
GO:0001836~release of 
cytochrome c from 
mitochondria 
8.47E-04 
BAK1, CASP7, BCL2L1 
66.640 0.386 0.115 1.236 
GO:0031967~organelle 
envelope 
1.02E-03 
BAK1, CASP7, BIK, BCL2L1, 
GPAM, MYOF, BCL2L11 
5.550 0.090 0.031 1.109 
Appendices 
 104
GO:0031975~envelope 
1.04E-03 
BAK1, CASP7, BIK, BCL2L1, 
GPAM, MYOF, BCL2L11 
5.533 0.091 0.024 1.127 
GO:0031968~organelle outer 
membrane 
1.06E-03 
BAK1, BCL2L1, GPAM, 
BCL2L11 
18.908 0.093 0.019 1.148 
GO:0005740~mitochondrial 
envelope 
1.14E-03 
BAK1, CASP7, BIK, BCL2L1, 
GPAM, BCL2L11 
7.040 0.100 0.017 1.240 
GO:0019867~outer 
membrane 
1.18E-03 
BAK1, BCL2L1, GPAM, 
BCL2L11 
18.208 0.103 0.015 1.280 
GO:0006915~apoptosis 
1.23E-03 
BAK1, CASP7, BIK, BCL2L1, 
CD24, MCF2L, BCL2L11 
5.424 0.509 0.133 1.796 
GO:0012501~programmed 
cell death 
1.33E-03 
BAK1, CASP7, BIK, BCL2L1, 
CD24, MCF2L, BCL2L11 
5.344 0.536 0.120 1.938 
GO:0043065~positive 
regulation of apoptosis 
1.70E-03 
BAK1, BIK, BCL2L1, CD24, 
MCF2L, BCL2L11 
6.509 0.625 0.131 2.470 
GO:0043068~positive 
regulation of programmed 
cell death 
1.75E-03 
BAK1, BIK, BCL2L1, CD24, 
MCF2L, BCL2L11 6.464 0.636 0.119 2.546 
GO:0010942~positive 
regulation of cell death 
1.79E-03 
BAK1, BIK, BCL2L1, CD24, 
MCF2L, BCL2L11 
6.434 0.644 0.108 2.598 
GO:0003006~reproductive 
developmental process 
1.95E-03 
BAK1, HSPA2, BIK, BCL2L1, 
BCL2L11 
8.902 0.676 0.106 2.829 
GO:0048608~reproductive 
structure development 
2.18E-03 
BAK1, BIK, BCL2L1, 
BCL2L11 
14.809 0.716 0.108 3.155 
GO:0007005~mitochondrion 
organization 
2.82E-03 
BAK1, CASP7, BCL2L1, 
CD24 
13.521 0.804 0.127 4.067 
GO:0006917~induction of 
apoptosis 
4.02E-03 
BAK1, BIK, CD24, MCF2L, 
BCL2L11 
7.289 0.902 0.163 5.741 
GO:0012502~induction of 
programmed cell death 
4.06E-03 
BAK1, BIK, CD24, MCF2L, 
BCL2L11 
7.266 0.904 0.154 5.803 
GO:0008584~male gonad 
development 
5.14E-03 
BIK, BCL2L1, BCL2L11 
26.912 0.949 0.179 7.287 
GO:0044429~mitochondrial 5.26E-03 BAK1, CASP7, BIK, BCL2L1, 4.957 0.384 0.059 5.597 
Appendices 
 105
part GPAM, BCL2L11 
GO:0042981~regulation of 
apoptosis 
5.28E-03 
BAK1, BIK, BCL2L1, DLG5, 
CD24, MCF2L, BCL2L11 
4.061 0.953 0.174 7.480 
GO:0043067~regulation of 
programmed cell death 
5.54E-03 
BAK1, BIK, BCL2L1, DLG5, 
CD24, MCF2L, BCL2L11 
4.021 0.959 0.172 7.835 
GO:0010941~regulation of 
cell death 
5.64E-03 
BAK1, BIK, BCL2L1, DLG5, 
CD24, MCF2L, BCL2L11 
4.007 0.962 0.166 7.971 
GO:0031966~mitochondrial 
membrane 
6.73E-03 
BAK1, CASP7, BCL2L1, 
GPAM, BCL2L11 
6.239 0.463 0.067 7.113 
Apoptosis 
7.21E-03 
BAK1, CASP7, BIK, BCL2L1, 
BCL2L11 
6.311 0.512 0.512 7.707 
GO:0016044~membrane 
organization 
7.43E-03 
BAK1, BCL2L1, CD24, EHD2, 
SH3GL2 
6.122 0.986 0.202 10.370 
GO:0046546~development of 
primary male sexual 
characteristics 
7.93E-03 
BIK, BCL2L1, BCL2L11 
21.530 0.990 0.205 11.033 
GO:0046661~male sex 
differentiation 
9.92E-03 
BIK, BCL2L1, BCL2L11 
19.171 0.997 0.239 13.615 
GO:0005829~cytosol 
1.16E-02 
BAK1, CASP7, UCHL1, 
BCL2L1, GPAM, MCF2L, 
BCL2L11, SH3GL2 
2.957 0.659 0.102 11.981 
GO:0008406~gonad 
development 
2.23E-02 
BIK, BCL2L1, BCL2L11 
12.495 1.000 0.446 28.217 
GO:0008624~induction of 
apoptosis by extracellular 
signals 
2.23E-02 
CD24, MCF2L, BCL2L11 
12.495 1.000 0.446 28.217 
GO:0007283~spermatogenesi
s 
2.51E-02 
HSPA2, BIK, BCL2L1, 
BCL2L11 
6.058 1.000 0.472 31.205 
GO:0048232~male gamete 
generation 
2.51E-02 
HSPA2, BIK, BCL2L1, 
BCL2L11 
6.058 1.000 0.472 31.205 
GO:0045137~development of 
primary sexual 
2.82E-02 
BIK, BCL2L1, BCL2L11 
11.019 1.000 0.497 34.293 
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characteristics 
GO:0007548~sex 
differentiation 
3.87E-02 
BIK, BCL2L1, BCL2L11 
9.268 1.000 0.597 43.999 
GO:0009628~response to 
abiotic stimulus 
3.96E-02 
BAK1, CASP7, BCL2L1, 
MYOF 
5.070 1.000 0.591 44.735 
GO:0046907~intracellular 
transport 
4.47E-02 
BAK1, UCHL1, BCL2L1, 
CD24, SH3GL2 
3.550 1.000 0.623 48.925 
GO:0007276~gamete 
generation 
4.72E-02 
HSPA2, BIK, BCL2L1, 
BCL2L11 
4.724 1.000 0.630 50.837 
GO:0031090~organelle 
membrane 
5.77E-02 
MTMR2, BAK1, CASP7, 
BCL2L1, GPAM, BCL2L11 
2.691 0.996 0.366 47.773 
GO:0009314~response to 
radiation 
6.40E-02 
BAK1, CASP7, BCL2L1 
6.997 1.000 0.731 62.117 
GO:0019953~sexual 
reproduction 
6.76E-02 
HSPA2, BIK, BCL2L1, 
BCL2L11 
4.074 1.000 0.739 64.224 
GO:0032504~multicellular 
organism reproduction 
7.82E-02 
HSPA2, BIK, BCL2L1, 
BCL2L11 
3.831 1.000 0.769 69.737 
GO:0048609~reproductive 
process in a multicellular 
organism 
7.82E-02 
HSPA2, BIK, BCL2L1, 
BCL2L11 3.831 1.000 0.769 69.737 
GO:0048534~hemopoietic or 
lymphoid organ development 
1.00E-01 
BAK1, CD24, BCL2L11 
5.382 1.000 0.842 78.857 
GO:0002520~immune 
system development 
1.11E-01 
BAK1, CD24, BCL2L11 
5.070 1.000 0.864 82.215 
GO:0006873~cellular ion 
homeostasis 
1.81E-01 
BAK1, BCL2L1, CD24 
3.742 1.000 0.943 94.642 
GO:0055082~cellular 
chemical homeostasis 
1.85E-01 
BAK1, BCL2L1, CD24 
3.683 1.000 0.944 95.057 
GO:0042592~homeostatic 
process 
2.01E-01 
BAK1, BCL2L1, CD24, 
BCL2L11 
2.485 1.000 0.951 96.323 
GO:0050801~ion 
homeostasis 
2.07E-01 
BAK1, BCL2L1, CD24 
3.422 1.000 0.952 96.687 
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GO:0042127~regulation of 
cell proliferation 
2.21E-01 
MARCKSL1, BCL2L1, DLG5, 
CD24 
2.371 1.000 0.956 97.447 
mitochondrion 
2.37E-01 
BCL2L1, COQ7, GPAM, 
BCL2L11 
2.312 1.000 0.978 95.029 
GO:0019725~cellular 
homeostasis 
2.51E-01 
BAK1, BCL2L1, CD24 
3.003 1.000 0.971 98.563 
GO:0048878~chemical 
homeostasis 
2.87E-01 
BAK1, BCL2L1, CD24 
2.733 1.000 0.983 99.299 
membrane 
3.83E-01 
EHBP1, BCL2L1, COQ7, 
BCL2L11, MCF2L, MTMR2, 
BAK1, MARCKS, BIK, CD24, 
DLG5, EHD2, GPAM, MYOF, 
SH3GL2 
1.153 1.000 0.987 99.527 
GO:0005886~plasma 
membrane 4.68E-01 
MARCKSL1, BCL2L1, DLG5, 
CD24, MYOF, EHD2, MCF2L, 
BCL2L11, SH3GL2 
1.171 1.000 0.937 99.899 
GO:0044459~plasma 
membrane part 
6.47E-01 
BCL2L1, DLG5, CD24, EHD2, 
MCF2L 
1.116 1.000 0.967 99.999 
cell membrane 
6.64E-01 
DLG5, CD24, MYOF, EHD2, 
MCF2L 
1.096 1.000 1.000 99.999 
GO:0031224~intrinsic to 
membrane 9.85E-01 
BAK1, BIK, MARCKS, 
BCL2L1, CD24, GPAM, 
MYOF 
0.627 1.000 1.000 100.000 
transmembrane region 
9.96E-01 
BAK1, BIK, BCL2L1, GPAM, 
MYOF 
0.486 1.000 1.000 100.000 
transmembrane 
9.96E-01 
BAK1, BIK, BCL2L1, GPAM, 
MYOF 
0.483 1.000 1.000 100.000 
GO:0016021~integral to 
membrane 
9.98E-01 
BAK1, BIK, BCL2L1, GPAM, 
MYOF 
0.464 1.000 1.000 100.000 
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Endocytosis Enrichment Score: 1.328  
Term P-Value Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GO:0016044~membrane 
organization 
7.43E-03 
BAK1, BCL2L1, CD24, EHD2, 
SH3GL2 
6.122 0.986 0.202 10.370 
GO:0006897~endocytosis 7.55E-02 CD24, EHD2, SH3GL2 6.361 1.000 0.767 68.432 
GO:0010324~membrane 
invagination 
7.55E-02 
CD24, EHD2, SH3GL2 
6.361 1.000 0.767 68.432 
GO:0016192~vesicle-
mediated transport 
1.15E-01 
MARCKSL1, CD24, EHD2, 
SH3GL2 
3.239 1.000 0.865 83.308 
 
 
SH3 Domain Enrichment Score: 1.132  
Term P-Value Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
domain:SH3 5.05E-02 DLG5, MCF2L, SH3GL2 8.099 1.000 0.924 46.127 
IPR001452:Src homology-3 
domain 
7.35E-02 
DLG5, MCF2L, SH3GL2 
6.518 1.000 0.978 57.159 
SM00326:SH3 1.08E-01 DLG5, MCF2L, SH3GL2 5.115 0.971 0.830 62.537 
 
Dimerization Enrichment Score: 1.0482  
Term P-Value Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GO:0031090~organelle 
membrane 
5.77E-02 
MTMR2, BAK1, CASP7, 
BCL2L1, GPAM, BCL2L11 
2.691 0.996 0.366 47.773 
GO:0046983~protein 
dimerization activity 
9.25E-02 
MTMR2, BAK1, SPEF2, 
BCL2L1 
3.549 1.000 0.991 65.818 
GO:0042802~identical 
protein binding 
1.34E-01 
MTMR2, BAK1, BCL2L1, 
SH3GL2 
3.005 1.000 0.991 79.690 
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Organelle Localization Enrichment Score: 0.3876  
Term P-Value Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GO:0005730~nucleolus 
1.54E-01 
TSR1, TARDBP, UCHL1, 
MYEF2 
2.817 1.000 0.666 83.830 
GO:0031981~nuclear lumen 
3.13E-01 
TSR1, TARDBP, CASP7, 
UCHL1, MYEF2 
1.695 1.000 0.885 98.357 
GO:0070013~intracellular 
organelle lumen 
4.67E-01 
TSR1, TARDBP, CASP7, 
UCHL1, MYEF2 
1.382 1.000 0.945 99.896 
GO:0043233~organelle 
lumen 
4.85E-01 
TSR1, TARDBP, CASP7, 
UCHL1, MYEF2 
1.351 1.000 0.930 99.930 
GO:0031974~membrane-
enclosed lumen 
5.02E-01 
TSR1, TARDBP, CASP7, 
UCHL1, MYEF2 
1.324 1.000 0.923 99.950 
GO:0043228~non-
membrane-bounded 
organelle 
5.95E-01 
TSR1, TARDBP, UCHL1, 
MYEF2, MARCKS, MYOF 1.136 1.000 0.954 99.995 
GO:0043232~intracellular 
non-membrane-bounded 
organelle 
5.95E-01 
TSR1, TARDBP, UCHL1, 
MYEF2, MARCKS, MYOF 1.136 1.000 0.954 99.995 
 
 
Cellular Localization Enrichment Score: 0.3586  
Term P-Value Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GO:0000267~cell fraction 
3.57E-01 
CASP7, CD24, EHD2, 
BCL2L11 
1.816 1.000 0.908 99.191 
GO:0005624~membrane 
fraction 
4.76E-01 
CD24, EHD2, BCL2L11 
1.823 1.000 0.933 99.914 
GO:0005626~insoluble 
fraction 
4.95E-01 
CD24, EHD2, BCL2L11 
1.758 1.000 0.927 99.943 
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Metal Ion Binding Enrichment Score: 0.1408  
Term P-Value Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
calcium 
2.22E-01 
EGFL6, PLA2G12A, 
PLA2G12B, EHD2 
2.395 1.000 0.984 93.775 
GO:0005509~calcium ion 
binding 
2.78E-01 
EGFL6, PLA2G12A, 
PLA2G12B, EHD2 
2.093 1.000 0.998 97.290 
Secreted 
8.68E-01 
EGFL6, PLA2G12A, 
PLA2G12B 
0.854 1.000 1.000 100.000 
metal-binding 
8.73E-01 
BAK1, ELOF1, PLA2G12A, 
PLA2G12B, COQ7 
0.809 1.000 1.000 100.000 
GO:0046872~metal ion 
binding 8.83E-01 
BAK1, EGFL6, ELOF1, 
PLA2G12A, PLA2G12B, 
COQ7, EHD2 
0.813 1.000 1.000 100.000 
GO:0043169~cation binding 
8.89E-01 
BAK1, EGFL6, ELOF1, 
PLA2G12A, PLA2G12B, 
COQ7, EHD2 
0.805 1.000 1.000 100.000 
GO:0043167~ion binding 
8.98E-01 
BAK1, EGFL6, ELOF1, 
PLA2G12A, PLA2G12B, 
COQ7, EHD2 
0.794 1.000 1.000 100.000 
GO:0005576~extracellular 
region 
9.22E-01 
EGFL6, PLA2G12A, 
PLA2G12B 
0.734 1.000 1.000 100.000 
signal 
9.71E-01 
EGFL6, PLA2G12A, 
PLA2G12B, CD24 
0.592 1.000 1.000 100.000 
signal peptide 
9.72E-01 
EGFL6, PLA2G12A, 
PLA2G12B, CD24 
0.588 1.000 1.000 100.000 
GO:0046914~transition 
metal ion binding 
9.85E-01 
BAK1, ELOF1, COQ7 
0.518 1.000 1.000 100.000 
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Transcription Factor 
Activity 
Enrichment Score: 0.0934 
Term P-Value Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GO:0003700~transcription 
factor activity 
5.92E-01 
MEOX2, TARDBP, MYEF2 
1.480 1.000 1.000 99.995 
GO:0030528~transcription 
regulator activity 
8.23E-01 
MEOX2, TARDBP, MYEF2 
0.954 1.000 1.000 100.000 
dna-binding 9.04E-01 MEOX2, TARDBP, MYEF2 0.772 1.000 1.000 100.000 
GO:0003677~DNA binding 9.61E-01 MEOX2, TARDBP, MYEF2 0.619 1.000 1.000 100.000 
 
Nucleotide Binding Enrichment Score: 0.07179  
Term P-Value Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GO:0000166~nucleotide 
binding 
6.81E-01 
HSPA2, RABL5, TARDBP, 
MYEF2, EHD2 
1.07 1.000 1.000 100.000 
nucleotide-binding 8.68E-01 HSPA2, RABL5, EHD2 0.86 1.000 1.000 100.000 
GO:0032555~purine 
ribonucleotide binding 
9.00E-01 
HSPA2, RABL5, EHD2 
0.79 1.000 1.000 100.000 
GO:0032553~ribonucleotide 
binding 
9.00E-01 
HSPA2, RABL5, EHD2 
0.79 1.000 1.000 100.000 
GO:0017076~purine 
nucleotide binding 
9.14E-01 
HSPA2, RABL5, EHD2 
0.75 1.000 1.000 100.000 
 
Appendix B:DAVID Analysis of Gene Ontology Enrichment. Genes are grouped into clusters based on their main function (ie: Cell Death 
Signalling). The enrichment score for each cluster is the geometric mean of the P value enrichment. Term column designates the Gene 
Ontology identifier. P-Value is Fisher Exact P score associated significance of enrichment in that function. Genes are given as official gene 
symbol. Fold enrichment is the ratio of genes involved in a GO term divided by the total number of input genes divided by the total number 
of genes in the background data set involved in that GO term, divded by the total number of background genes. Bonferroni and Benjamini 
values are multiple testing corrected P-values and FDR is the false discovery rate. 
 
 
